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and outline of the thesis
HYPERTENSION
Hypertension is a common medical condition and its incidence is increasing. The available 
data on the prevalence of hypertension and the temporal trends of blood pressure (BP) values 
in different European countries suggest that the overall prevalence of hypertension appears 
to affect approximately 30–45% of the general population, with a clear increase with ageing. 
There also appears to be noticeable differences in the average BP levels across countries, 
with no systematic trends towards BP changes in the past decade1–21. Globally, the overall 
prevalence of raised BP in adults aged 25 and over was around 40% in 2008. The proportion 
of the world’s population with high BP (>140/90 mmHg), or uncontrolled hypertension, fell 
modestly between 1980 and 2008. However, because of population growth and ageing, the 
number of patients with uncontrolled hypertension rose from 600 million in 1980 to nearly 
1 billion in 200822. Across the World Health Organization (WHO) regions, the prevalence of 
raised BP was highest in Africa, where it was 46% for both sexes combined. Both men and 
women have high rates of elevated BP in the Africa region, with prevalence rates over 40%. The 
lowest prevalence of raised BP was in the WHO region of the Americas at 35% for both sexes. 
Men in this region had higher prevalence than women (39% for men and 32% for women). In all 
WHO regions, men have slightly higher prevalence of raised BP than women. This difference 
was only statistically significant in the Americas and Europe.
  
The BP taken during a visit to the treating physician (Office BP) is a known independent 
risk factor for major cardiovascular events such as atrial fibrillation (AF), stroke, myocardial 
infarction, sudden death, left ventricular hypertrophy, heart failure and peripheral artery 
disease as well as of end-stage renal disease23-25. This relationship has been established at all 
ages and in all ethnic groups26,27. A continuous relationship with events is also exhibited by 




Despite the high prevalence of hypertension and its associated complications, control of the 
condition is by far not satisfying. Although the awareness rate of hypertension increased and 
both treatment and control of hypertension have improved over the past few decades, data 
from NHANES 2005-2008 show that only 50.1% of persons with hypertension have their BP under 
control. Control of hypertension was defined as a level below 140/90 mmHg. This demonstrates 
that treatment still has a long way to go28. In a large Dutch registry HELIUS similar differences 
in hypertension control among the native Dutch population and ethnic minorities were 
observed. The native Dutch population demonstrated hypertension control in 53% of men and 
61% of women. Minorities within the Dutch population demonstrated adequate control in 43% 
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of the South-Asian Surinamese population, but only 23% in Ghanaian men. These data show 
that hypertension control can be improved in the native Dutch population, but many ethnic 
minorities could benefit from even closer attention and subsequent treatment29.
MEDICAL TREATMENT OF HYPERTENSION
Large randomized trials have shown that antihypertensive therapy is associated with a nearly 
50 percent relative risk reduction in the incidence of heart failure. The relative risk reduction 
in stroke is estimated between 30 to 40 percent. Although less pronounced, antihypertensive 
treatment produces a 20 to 25 percent relative risk reduction for myocardial infarction.30 These 
relative risk reductions correspond to the following absolute benefits: antihypertensive therapy 
for four to five years prevents a coronary event in 0.7 percent of patients and a cerebrovascular 
event in 1.3 percent of patients for a total absolute benefit of approximately 2 percent31. Thus, 
100 patients must be treated for four to five years to prevent a complication in two patients. 
  
However, data for this estimation are derived from trials with a follow up of five to seven years. 
Therefore, we assume that the true benefit of antihypertensive treatment is underestimated.
Medical therapy aims to lower BP to avoid the mentioned cardiovascular events. Multiple 
guidelines have been developed to help set up goals for BP reduction. Meta-analyses 
conclude that primarily the degree of BP reduction, and not a specific drug regimen, is the 
major determinant of cardiovascular risk reduction in patients with hypertension30,32-34. 
Recommendations for the use of specific classes of antihypertensive medications are based 
upon clinical trial evidence of decreased cardiovascular risk, BP-lowering efficacy, safety, 
and tolerability. Most patients with hypertension will require more than one BP medication 
to reach the determined goal BP. Medical therapy should be based upon individual patient 
characteristics and physician’s preferences.
RESISTANT HYPERTENSION VS. SECONDARY HYPERTENSION
Resistant hypertension is defined as BP that is not controlled, despite adherence to an 
appropriate ≥three-drug regimen (including a diuretic) in which all drugs are dosed at 50 
percent or more of the maximum recommended antihypertensive dose; or BP that requires at 
least four medications to achieve control35. 
  
Approximately 15 percent of patients diagnosed with hypertension appear to have resistant 
hypertension. However, many patients who appear to have resistant hypertension may 
actually display pseudo resistance rather than true resistance. 
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Pseudo resistance may result from one or more of the following issues: 
•	 Inaccurate BP measurement (e.g., use of an inappropriately small BP cuff).
•	 Inadequate screening methods for secondary hypertension
•	 Poor compliance to BP medications
•	 Poor compliance to lifestyle and dietary approaches to lower BP
•	 Suboptimal antihypertensive therapy, due either to inadequate doses or exclusion of a 
diuretic from the antihypertensive regimen
•	 White coat resistance; as an example, a Spanish study found that 35 percent of patients 
with apparent treatment-resistant hypertension actually had well-controlled BP by 
ambulatory monitoring, suggesting they had white coat hypertension as a cause of their 
resistance36
Patients with resistant hypertension referred for renal denervation were systematically 
screened for secondary causes. In Isala Hospital, resistant hypertensive patients are screened 
according to a vigorous protocol. One of the most common causes to be found through 
screening is hyperaldosteronism. The hormonal screening performed in our hospital is an 
effective approach to exclude this frequently encountered and otherwise asymptomatic cause 
of hypertension. A different approach is to treat all patients referred for resistant hypertension 
with a drug regimen including an MRA (mineralocorticoid receptor antagonist) and monitor 
the effect. We diagnosed hyperaldosteronism in approximately 10% of the so called resistant 
hypertension patients with. Medical therapy is the mainstay of treatment in these patients. 
A trial period including an MRA is limited by drug compliance. We believe that hormonal 
screening is preferred over adding another drug to the current regimen, lowering compliance. 
Resistant hypertension and the research regarding this field are plagued by poor drug 
compliance. Researchers from the University Medical Center Utrecht (UMCU) have published 
the results of the SYMPATHY study. A unique feature of this study was measurements of plasma 
levels of the prescribed antihypertensive drugs. A shocking 20% of patients had adequate 
levels of all their prescribed drugs, leaving 80% of the patients without adequate levels 
(or in a much smaller portion with plasma levels of different antihypertensive drugs than 
currently prescribed)37. The treating physicians should do what is in their power to improve 
drug adherence, however achievement of an adherence of 100% is not realistic. Therefore, 
interventional therapy might be a good alternative to a life time challenge of drug adherence, 
especially in a patient population dealing with such poor drug adherence. 
When true resistance has been established, another issue rises. Many underlying diseases can 
manifest as drug resistant hypertension. These types of disorders are classified as secondary 
hypertension. There is a number of general clinical clues that are suggestive of secondary 
hypertension and require further investigation: 
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•	 An acute rise in BP developing in a patient with previously stable values.
•	 Age less than 30 years in non-obese, non-black patients with a negative family history of 
hypertension and no other risk factors (e.g., obesity) for hypertension.
•	 Malignant or accelerated hypertension (e.g., patients with severe hypertension and 
signs of end-organ damage such as retinal haemorrhages or papilledema, heart failure, 
neurologic disturbance, or acute kidney injury). 
•	 Proven age of onset before puberty. 
Renovascular hypertension is the most common potentially correctable cause of secondary 
hypertension. The incidence varies with the clinical setting. It probably occurs in less than 1 
percent of patients with mild hypertension38. By comparison, between 10 and 45% of white 
patients with severe or malignant hypertension has renal artery stenosis. 
Renal artery stenosis can be detected in many individuals with other manifestations of 
atherosclerosis, such as coronary artery disease (10 to 14 percent) and peripheral arterial and 
aortic disease (24 to 35 percent)39.
Several clinical features should bring the physician to exclude renovascular disease. For 
example, new onset of severe hypertension (BP ≥180 mmHg systolic and/or 120 mmHg 
diastolic) after the age of 55 years. Also, an unexplained deterioration of kidney function 
during antihypertensive therapy, especially an acute and sustained elevation in the serum 
creatinine concentration by more than 50 percent that occurs within one week of starting 
a drug regimen that includes an angiotensin-converting enzyme (ACE) inhibitor or 
angiotensin II receptor blocker (ARB) should alert physicians. Due to the vasoconstrictive 
effect of these agents, severe kidney function deterioration can be observed. Hypertension 
in patients with other atherosclerotic diseases, particularly those over age 50 is another clue. 
Severe hypertension in patients with recurrent episodes of acute (flash) pulmonary edema or 
refractory heart failure with impaired renal function should prompt physicians as well40. In 
a series of 55 patients with renovascular hypertension, for example, 23 percent had recurrent 
episodes of pulmonary edema requiring hospitalization. Flash pulmonary edema was more 
common in patients with bilateral compared with unilateral renal artery stenosis. Factors 
that contribute to acute cardiac decompensation include a hypertension-induced increase 
in afterload, inability of a hypertrophied left ventricle to relax in diastole (i.e., diastolic 
with or without systolic LV dysfunction), sodium retention due to activation of the renin-
angiotensin-aldosterone system, and associated renal dysfunction41,42. Registry data from the 
United Kingdom indicate that patients with episodes of pulmonary edema and renal artery 
stenosis have a benefit of reduced mortality after successful renal revascularization43. Since 
antihypertensive drug therapy can lead to kidney function deterioration, imaging is often 
indicated.
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Hormonal disturbances can cause drug resistant hypertension in different ways. As discussed 
earlier, hyperaldosteronism is the most common hormonal cause. The main clinical clue 
suggestive of primary hyperaldosteronism is otherwise unexplained or easily provoked 
hypokalaemia. High levels of aldosterone induce potassium wasting in the kidneys in exchange 
for sodium. However, more than one-half of patients have a normal serum potassium levels. 
Therefore, nearly all patients with suspected secondary hypertension should be evaluated for 
primary hyperaldosteronism. Primary hyperaldosteronism should also be suspected in the 
presence of slight hypernatremia, drug-resistant hypertension, and/or hypertension with an 
adrenal incidentaloma. Measurements of the ratio of the plasma aldosterone concentration 
to plasma renin activity can help identify such patients44, although inappropriate elevation 
of aldosterone is also a common feature in obese patients45. 
Obstructive sleep apnoea syndrome (OSAS) is another cause of secondary hypertension 
that can be treated, for example by continuous positive airway pressure. Patients have 
multiple apnoeic episodes at night due to passive collapse of the pharyngeal muscles during 
inspiration, such that the airway becomes occluded from the apposition of the tongue and 
soft palate against the posterior oropharynx. Other symptoms of OSAS include headache, 
daytime somnolence and fatigue, morning confusion with difficulty in concentration, 
personality changes, depression, persistent systemic hypertension, and potentially life-
threatening cardiac arrhythmias46. Patients with obstructive sleep apnoea often retain 
sodium and fail to respond optimally to antihypertensive drug therapy47. Correction of the 
sleep apnoea may improve BP control48. Other causes of secondary hypertension, including 
primary kidney disease, use of oral contraceptives, and the more exotic underlying diseases 
such as pheochromocytoma, Cushing’s syndrome, and coarctation of the aorta must also be 
excluded in the appropriate settings.
RENAL SYMPATHETIC DENERVATION
When all causes of apparent resistant hypertension have been excluded, a subset of patients 
is diagnosed with true resistant hypertension. This subset of patients is at high risk of 
developing cardiovascular complications. For this group medical therapy falls short and 
other solutions are warranted. Renal denervation (RDN) is a non-pharmacological treatment 
option for patients with resistant hypertension. 
RDN is a procedure using a percutaneous transarterial approach. Catheter ablation of the 
renal sympathetic nerve tissue is performed by delivering RF energy through electrodes 
positioned in the renal arterial wall. Ablation lesions are rotationally and longitudinally 
applied in a spiral pattern to the renal artery to ablate the renal nerves under fluoroscopic 
guidance (Figure 1 and 2).
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Figure 1. The RDN catheter set up consists of three parts. The generator supplies the energy for radio frequency 
ablation. The guiding wire helps position the ablation catheter. The actual ablation catheter delivers the radio 
frequency energy to the renal arterial wall for subsequent destruction of the surrounding nerve tissue. Two different 
types are shown: EnligHTN by St. Jude Medical in the left and in the right panel Spyral by Medtronic.
RDN is supported by a solid rationale, including reports from the years 1940-6049-52. During 
those times, radical surgery was performed for sympathetic denervation, successfully 
lowering BP. However, also in these patients a percentage appeared to be non-responders. 
Nammas et al. described the cardiorenal sympathetic interaction53. Deleterious effects of 
chronically increased sympathetic tone on the cardiorenal axis are well known54. However, 
neural connections between the central and peripheral autonomic system remain very 
complex. Tsai et al. provided further insights into the cardiorenal neural connections in a 
canine model55. The investigators provided histopathological proof of damage to nerves in 
the stellate ganglion and medulla in healthy dogs in the weeks following RDN. Besides the 
histological proof, functional measurements with radio transmitters on the stellate ganglia 
and vagal nerve demonstrate decreased stellate ganglion activity and a significant reduction 
of both duration and frequency of atrial tachyarrhythmia episodes after RDN. This study 
clearly demonstrated that RDN leads to central as well as to peripheral sympathetic nervous 
system denervation. Among other cardiovascular diseases, AF is a condition that is influenced 
by the autonomic nervous system. Therefore this study provides insight in the crosstalk 
between the autonomic nervous system, the heart and the possibility to influence this system 
by targeting the autonomic nervous system. The autonomous nerve connections to heart are 
visualized in Figure 2. 
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Figure 2. The cardiac sympathetic ganglia consist of cervical ganglia, stellate (cervicothoracic) ganglia, and 
thoracic ganglia. Parasympathetic innervation originate from the vagal nerves. Reprinted from Shen et al12 with 
permission of the publisher. Copyright © 2011, Nature Publishing Group. Authorization for this adaptation has 
been obtained both from the owner of the copyright in the original work and from the owner of copyright in the 
translation or adaptation.
 
The initial successes of studies regarding renal sympathetic denervation created a promise 
of one form of solution for resistant hypertension. Several unblinded studies suggested that 
renal denervation could substantially lower BP in patients with resistant hypertension55-64. 
These studies have raised quite an interest in RDN.
As an example, an open-label randomized trial (DENERHTN) compared stepped 
antihypertensive therapy alone with stepped antihypertensive therapy plus renal denervation 
in 106 patients with confirmed resistant hypertension despite therapy with indapamide, 
amlodipine, and ramipril (or irbesartan if allergic to angiotensin-converting enzyme 
inhibitors)65. Stepped antihypertensive therapy consisted of spironolactone, bisoprolol, 
prazosin, and rilmenidine added (in that order) at monthly intervals if home BP remained 
above 135/85 mmHg. At six months, the decrease in 24-hour ambulatory systolic pressure was 
significantly more in the renal denervation group (-15.4 versus -9.5 mmHg). However, this 
study had several limitations. In addition to the lack of a sham intervention, all patients 
lost to follow-up were in the denervation group and were not analysed, also the number 
of antihypertensive medications used at six months was similar in both groups. Baseline 
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BP was higher in the denervation group, implying that the results could be due in part to 
regression to the mean. Regression to the mean is a prominent pitfall in hypertension studies. 
A considerably smaller trial found that spironolactone lowered 24-hour ambulatory systolic 
pressure more than renal denervation66. 
A blinded randomized trial (SYMPLICITY-HTN-3) failed to demonstrate benefit of RDN67,68. In 
SYMPLICITY-HTN-3 trial, 535 patients with treatment-resistant hypertension (systolic pressure 
>160 mmHg despite three or more antihypertensive medications, including a diuretic) were 
assigned to renal denervation or a sham procedure; BP decreased to a similar degree in both 
groups at six months, and there was no difference in the incidence of serious adverse events. 
Due to the lack of benefit, the inclusion in a larger ongoing international trial (SYMPLICITY-
HTN-4) was stopped prematurely. Two additional, smaller sized sham-controlled trials 
confirmed the findings of the SYMPLICITY-HTN-3 trial69,70.
The current state of RDN in the setting of uncontrolled hypertension is established in the Joint 
Position Paper on Renal Denervation. Further research is encouraged to better select patients 
that might benefit from renal denervation. Patient selection can be divided into different 
factors that differ between patients. For example, the anatomy of the renal vasculature 
might be a reason to refrain from RDN (Okada classification). Another factor that should be 
considered is vascular resistance as a contributor to the development of hypertension. And 
major concern regarding RDN is the lack of a procedural endpoint71.
The autonomic nervous system, particularly the imbalance between sympathetic and vagal 
hyperactivity, plays an important role in the initiation, maintenance and perpetuation of 
atrial tachycardia/atrial fibrillation72,73. Animal models, for example the rabbit model for atrial 
fibrosis reported by Wei and colleagues, demonstrated less inducibility of AF after RDN74. An 
interesting study by Yu et al. demonstrated the effect of renal sympathetic stimulation (RSS) 
on the effective refractory period and the window of vulnerability. This paper concludes 
that RSS leads to an increase in sympathetic tone and an increase in inducibility of AF 
in a dog model75. Coumel et al. first reported on the importance of vagal and sympathetic 
hyperactivity in the genesis of atrial arrhythmias in humans76-78. Arora et al demonstrated 
an abundance of parasympathetic fibres in the posterior wall of the left atrium which 
have distinctive anatomic, molecular, and electrophysiological properties that favour the 
development and maintenance of AF79. The mechanism of arrhythmia triggering through the 
cardiorenal axis may be initiated by activation of the mechanoreceptors in the renal pelvic 
wall and chemoreceptors in the renal interstitium with stimuli, such as ischemia, hypoxia or 
intrinsic renal disease. Stimulation of these receptors may lead to renal afferent sympathetic 
signalling through the hypothalamus, followed by increased central sympathetic outflow and 
efferent sympathetic nerve signalling to the heart, which leads to enhanced automaticity and 
triggered activity. Figure 3 summarizes the discussed interactions elegantly. The currently 
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available data on the role of RDN in cardiac arrhythmogenesis have been summarized well 
in a review by Linz et al., suggesting an ongoing role for RDN in the setting of atrial (and 
ventricular) arrhythmia80.
Figure 3. Mechanisms by which autonomic tone can promote AF. Top, Action potential changes showing cellular 
mechanisms by which adrenergic activation can lead to focal ectopic firing. Black dotted tracings represent normal 
reference action potentials in each panel. A, Enhanced automaticity. B, Early afterdepolarizations (EADs). C, Delayed 
afterdepolarization (DADs). Contributions from adrenergic activation alone are shown by red tracings, whereas that 
from cholinergic activation (combined with adrenergic activation) by green tracings. Adrenergic stimulation in the 
setting of impaired repolarization reserve can cause phase-2 EADs (red dashed tracings in B). Most phase-3 EADs are 
also associated with prolonged action potential duration (APD; blue dashed tracings in B). Combined adrenergic/
vagal discharge can produce late phase-3 EADs (green dashed tracings in B) because of a prolonged and enhanced 
Ca2+ transient that outlasts IKACh-induced accelerated repolarization. D, Tissue-level arrhythmia mechanisms, with 
focal ectopic activity maintaining AF as a driver or acting on vulnerable re-entrant substrates. Parasympathetic firing 
discharges acetylcholine, producing spatially heterogeneous action potential and refractory period abbreviation that 
promotes the occurrence and maintenance of re-entrant activity. CaT indicates calcium transient; LA, left atrium; 
NCX, sodium calcium exchanger; RA, right atrium; RyR, ryanodine receptor; and SR, sarcoplasmic reticulum.
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AIM AND OUTLINE
Excluding the general introduction (chapter 1) and the discussion (chapter 8), the thesis 
consists of six chapters. Each chapter discusses a different aspect of RNS and RDN. Chapter 2 
discusses the feasibility of RNS during RDN procedures in humans while studying different 
output settings and pacing settings. Renal nerve stimulation was only performed in animal 
models prior to this publication. We used RNS to establish it as a predictor of clinical 
response to RDN based on ABPM data in chapter 3. The correlation between the RNS-induced 
changes in BP and the differences in 24 hour ambulatory BP proved to be significant. Chapter 
4 demonstrates that accessory arteries elicit an impressive increase in BP in response to RNS, 
possibly explaining the mechanism behind the sympathetic innervation of accessory arteries. 
Therefore, renal denervation is less likely to be effective in patients with a more complex renal 
vasculature involving smaller accessory arteries that cannot be denervated with the current 
technology. 
Chapter 5 discusses the different patterns of BP response to RNS. The different patterns 
possibly explain the different physiological structures that are being stimulated during RNS. 
An invited review discussing RNS as a procedural endpoint to RDN is described in chapter 
6. A final step in this thesis is the start of a currently ongoing trial investigating the role of 
RDN in the setting of AF. The ASAF study design is described chapter 7, discussing the clinical 
background and rationale of investigating RDN as a treatment option on top of pulmonary 
vein isolation in a multicenter randomized clinical trial. 
19
RENAL SYMPATHETIC DENERVATION: RENAL NERVE STIMULATION 
1
REFERENCES
1. Danon-Hersch N, Marques-Vidal P, Bovet P, Chiolero A, Paccaud F, Pecoud A, Hayoz D, Mooser V,Waeber G, 
Vollenweider P. Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general 
population: the CoLaus study. Eur J Cardiovasc Prev Rehabil 2009;16:66–72.
2. Altun B, Arici M, Nergizoglu G, Derici U, Karatan O, Turgan C, Sindel S, Erbay B, Hasanoglu E, Caglar S. Prevalence, 
awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003. J Hypertens 2005;23:1817–1823.
3. Tugay Aytekin N, Pala K, Irgil E, Akis N, Aytekin H. Distribution of blood pressures in Gemlik District, north-west 
Turkey. Health Soc Care Community 2002;10:394–401.
4. Efstratopoulos AD, Voyaki SM, Baltas AA, Vratsistas FA, Kirlas DE, Kontoyannis JT, Sakellariou JG, Triantaphyllou GB, 
Alokrios GA, Lianas DN, Vasilakis EA, Fotiadis KN, Kastritsea EE. Prevalence, awareness, treatment and control of 
hypertension in Hellas, Greece: the Hypertension Study in General Practice in Hellas (HYPERTENSHELL) national 
study. Am J Hypertens 2006;19:53–60.
5. Macedo ME, Lima MJ, Silva AO, Alcantara P, Ramalhinho V, Carmona J. Prevalence, awareness, treatment and 
control of hypertension in Portugal: the PAP study. J Hypertens 2005;23:1661–1666.
6. Psaltopoulou T, Orfanos P, Naska A, Lenas D, Trichopoulos D, Trichopoulou A. Prevalence, awareness, treatment 
and control of hypertension in a general population sample of 26,913 adults in the Greek EPIC study. Int J Epidemiol 
2004;33:1345–1352.
7. Sarafidis PA, Lasaridis A, Gousopoulos S, Zebekakis P, Nikolaidis P, Tziolas I, Papoulidou F. Prevalence, awareness, 
treatment and control of hypertension in employees of factories of Northern Greece: the Naoussa study. J Hum 
Hypertens 2004;18:623–629.
8. Panagiotakos DB, Pitsavos CH, Chrysohoou C, Skoumas J, Papadimitriou L, Stefanadis C, Toutouzas PK. Status and 
management of hypertension in Greece: role of the adoption of a Mediterranean diet: the Attica study. J Hypertens 
2003;21:1483–1489.
9. Banegas JR, Graciani A, de la Cruz-Troca JJ, Le´on-Munoz LM, Guallar-Castillo`n P, Coca A, Ruilope LM, Rodriguez-
Artalejo F. Achievement of cardiometabolic targets in aware hypertensive patients in Spain: a nationwide 
population-based study. Hypertension 2012;60:898–905.
10. Primatesta P, Poulter NR. Improvement in hypertension management in England: results from the Health Survey 
for England 2003. J Hypertens 2006;24:1187–1192.
11. Meisinger C, Heier M, Volzke H, Lowel H, Mitusch R, HenseHW, Ludemann J. Regional disparities of hypertension 
prevalence and management within Germany. J Hypertens 2006;24:293–299.
12. Agyemang C, Ujcic-Voortman J, Uitenbroek D, Foets M, Droomers M. Prevalence and management of hypertension 
among Turkish, Moroccan and native Dutch ethnic groups in Amsterdam, the Netherlands: The Amsterdam Health 
Monitor Survey. J Hypertens 2006;24:2169–2176.
13. Agyemang C, Bindraban N, Mairuhu G, Montfrans G, Koopmans R, Stronks K. Prevalence, awareness, treatment and 
control of hypertension among Black Surinamese, South Asian Surinamese and White Dutch in Amsterdam, The 
Netherlands: the SUNSET study. J Hypertens 2005;23:1971–1977.
14. Scheltens T, Bots ML, Numans ME, Grobbee DE, Hoes AW.Awareness, treatment and control of hypertension: the 
’rule of halves’ in an era of risk-based treatment of hypertension. J Hum Hypertens 2007;21:99–106.
15. Zdrojewski T, Szpakowski P, Bandosz P, Pajak A, Wiecek A, Krupa-Wojciechowska B, Wyrzykowski B. Arterial 
20
RENAL SYMPATHETIC DENERVATION: RENAL NERVE STIMULATION 
1
hypertension in Poland in 2002. J Hum Hypertens 2004;18:557–562.
16. Cifkova R, Skodova Z, Lanska V, Adamkova V, Novozamska E, Jozifova M, Plaskova M, Hejl Z, Petrzilkova Z, Galovcova 
M, Palous D. Prevalence, awareness, treatment and control of hypertension in the Czech Republic. Results of 
two nationwide cross-sectional surveys in 1997/1998 and 2000/2001, Czech Post-MONICA Study. J Hum Hypertens 
2004;18:571–579.
17. Scuteri A, Najjar SS, Orru M, Albai G, Strait J, Tarasov KV, Piras MG, Cao A, Schlessinger D, Uda M, Lakatta EG. Age- and 
gender-specific awareness, treatment and control of cardiovascular risk factors and subclinical vascular lesions in 
a founder population: the SardiNIA Study. Nutr Metab Cardiovasc Dis 2009;19:532–541.
18. Kastarinen M, Antikainen R, Peltonen M, Laatikainen T, Barengo NC, Jula A, Salomaa V, Jousilahti P, Nissinen A, 
Vartiainen E, Tuomilehto J. Prevalence, awareness and treatment of hypertension in Finland during 1982–2007. J 
Hypertens 2009;27:1552–1559.
19. Falaschetti E, Chaudhury M, Mindell J, Poulter N. Continued improvement in hypertension management in 
England: results from the Health Survey for England 2006. Hypertension 2009;53:480–486.
20. 20. Erem C, Hacihasanoglu A, Kocak M, Deger O, Topbas M. Prevalence of prehypertension and hypertension and 
associated risk factors among Turkish adults: Trabzon Hypertension Study. J Public Health (Oxf) 2009;31:47–58.
21. Costanzo S, Di Castelnuovo A, Zito F, Krogh V, Siani A, Arnout J, Cappuccio FP, Miller MA, van Dongen M, de 
Lorgeril M, de Gaetano G, Donati MB, Iacoviello L. Prevalence, awareness, treatment and control of hypertension 
in healthy unrelated male-female pairs of European regions: the dietary habit profile in European communities 
with different risk of myocardial infarction: the impact of migration as a model of gene-environment interaction 
project. J Hypertens 2008;26:2303–2311.
22. WHO Global InfoBase. Global Health Observatory (GHO) data Risk factors. [http://www.who.int/gho/ncd/risk_
factors/blood_pressure_prevalence_text/en/ (last checked 2nd of April 2018)]
23. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular 
mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–
1913.
24. Britton KA, Gaziano JM, Djousse L. Normal systolic blood pressure and risk of heart failure in US male physicians. 
Eur J Heart Fail 2009;11:1129–1134.
25. Kalaitzidis RG, Bakris GL. Prehypertension: is it relevant for nephrologists? Kidney Int 2010;77:194–200.
26. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J 
Hypertens 2003;21:707–716.
27. Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. 
Am J Hypertens 2007;20:338–341.
28. Adapted from: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure, JAMA 2003; 289:2560, and from US Trends in Prevalence, Awareness, Treatment, 
and Control of Hypertension 1988-2008, JAMA 2010; 303:2043.
29. Agyemang C, Kieft S, Snijder MB, Beune EJ, van den Born BJ, Brewster LM, Ujcic-Voortman JJ, Bindraban N, van 
Montfrans G, Peters RJ, Stronks K. Hypertension control in a large multi-ethnic cohort in Amsterdam, The 
Netherlands: the HELIUS study. Int J Cardiol. 2015; 183:180-9.
30. Blood Pressure Lowering Treatment Trialists’ Collaboration, Turnbull F, Neal B, et al. Effects of different regimens 
to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised 
21
RENAL SYMPATHETIC DENERVATION: RENAL NERVE STIMULATION 
1
trials. BMJ 2008; 336:1121.
31. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and 
decreased risk of coronary heart disease. Arch Intern Med 1993; 153:578.
32. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the 
Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the 
European Society of Cardiology (ESC). J Hypertens 2013; 31:1281.
33. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of 
ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood 
Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 
115:2761.
34. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: 
meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. 
BMJ 2009; 338:b1665.
35. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart 
Association Professional Education Committee of the Council for High Blood Pressure Research. Calhoun DA, 
Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, 
Falkner B, Carey RM. Hypertension 2008;51(6):1403.
36. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure 
monitoring. De la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. 
Hypertension 2011;57(5):898.
37. de Jager RL, van Maarseveen EM, Bots ML, Blankestijn PJ; SYMPATHY investigators. Medication adherence in 
patients with apparent resistant hypertension: findings from the SYMPATHY trial. Br J Clin Pharmacol. 2018;84:18-24.
38. Lewin A, Blaufox MD, Castle H, et al. Apparent prevalence of curable hypertension in the Hypertension Detection 
and Follow-up Program. Arch Intern Med 1985; 145:424.
39. Textor SC, Lerman L. Renovascular hypertension and ischemic nephropathy. Am J Hypertens 2010; 23:1159.
40. Kane GC, Xu N, Mistrik E, et al. Renal artery revascularization improves heart failure control in patients with 
atherosclerotic renal artery stenosis. Nephrol Dial Transplant 2010; 25:813.
41. Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. 
N Engl J Med 2001; 344:17.
42. Messerli FH, Bangalore S, Makani H, et al. Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering 
syndrome. Eur Heart J 2011; 32:2231.
43. Ritchie J, Green D, Chrysochou C, et al. High-risk clinical presentations in atherosclerotic renovascular disease: 
prognosis and response to renal artery revascularization. Am J Kidney Dis 2014; 63:186.
44. Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al. Validity of plasma aldosterone-to-renin activity ratio in African 
American and white subjects with resistant hypertension. Am J Hypertens 2005; 18:805.
45. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. 
Hypertension 2004; 43:518.
46. Selim BJ, Koo BB, Qin L, Jeon S, Won C, Redeker NS, Lampert RJ, Concato JP, Bravata DM, Ferguson J, Strohl K, Bennett 
A, Zinchuk A, Yaggi HK. The Association between Nocturnal Cardiac Arrhythmias and Sleep-Disordered Breathing: 
The DREAM Study. J Clin Sleep Med 2016:15;12:829-37.
22
RENAL SYMPATHETIC DENERVATION: RENAL NERVE STIMULATION 
1
47. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant 
hypertension. J Hypertens 2001; 19:2271.
48. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/
American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for 
High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, 
and Council on Cardiovascular Nursing. J Am Coll Cardiol 2008; 52:686.
49. Page IH, Heuer GJ. The effect of renal denervation on the level of arterial blood pressure and renal function in 
essential hypertension. J Clin Invest 1935;14:27-30.
50. Kottke FJ, Kubicek WG, Visscher MB. The production of arterial hypertension by chronic renal artery-nerve 
stimulation. Am J Physiol 1945;145:38-47.
51. Smithwick RH. Surgical treatment of hypertension. Am J Med 1948;4:744-59.
52. Kubicek WG, Kottke FJ, Laker DJ, Visscher MB. Renal function during arterial hypertension produced by chronic 
splanchnic nerve stimulation in the dog. Am J Physiol 1953;174:397-400.
53. Nammas W, Airaksinen JKE, Paana T, Karjalainen PP. Renal sympathetic denervation for treatment of patients with 
atrial fibrillation: Reappraisal of the available evidence. Heart Rhythm. 2016 Dec;13(12):2388–94. 
54. Elvan A, Zipes DP. Right ventricular infarction causes heterogeneous autonomic denervation of the viable peri-
infarct area. Circulation. 1998 Feb 10;97(5):484–92. 
55. Tsai W-C, Chan Y-H, Chinda K, Chen Z, Patel J, Shen C, et al. Effects of renal sympathetic denervation on the stellate 
ganglion and brain stem in dogs. Heart Rhythm. 2017 Feb;14(2):255–62.
Symplicity HTN-2 Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-
resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903.
56. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: 
a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275.
57. Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J 
Med 2009; 361:932.
58. Williams B. Resistant hypertension: an unmet treatment need. Lancet 2009; 374:1396.
59. Davis MI, Filion KB, Zhang D, et al. Effectiveness of renal denervation therapy for resistant hypertension: a 
systematic review and meta-analysis. J Am Coll Cardiol 2013; 62:231.
60. Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation 
in patients with resistant hypertension. Circulation 2013; 128:132.
61. Worthley SG, Tsioufis CP, Worthley MI, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation 
system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013; 34:2132.
62. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: 
durability of blood pressure reduction out to 24 months. Hypertension 2011; 57:911.
63. Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23:1250.
64. Kiuchi MG, Maia GL, de Queiroz Carreira MA, et al. Effects of renal denervation with a standard irrigated cardiac 
ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant 
hypertension. Eur Heart J 2013; 34:2114.
65. Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or 
without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised 
23
RENAL SYMPATHETIC DENERVATION: RENAL NERVE STIMULATION 
1
controlled trial. Lancet 2015; 385:1957.
66. 66. Oliveras A, Armario P, Clarà A, et al. Spironolactone versus sympathetic renal denervation to treat true resistant 
hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens 2016; 34:1863.
67. 67. Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N 
Engl J Med 2014; 370:1393.
68. 68. Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med 2014; 370:1454.
69. 69. Desch S, Okon T, Heinemann D, et al. Randomized sham-controlled trial of renal sympathetic denervation in 
mild resistant hypertension. Hypertension 2015; 65:1202.
70. 70. Mathiassen ON, Vase H, Bech JN, et al. Renal denervation in treatment-resistant essential hypertension. A 
randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens 2016; 34:1639.
71. 71. Executive Summary of the Joint Position Paper on Renal Denervation of the Cardiovascular and Interventional 
Radiological Society of Europe (CIRSE) and the European Society of Hypertension (ESH) Jonathan G. Moss, 
corresponding author, Anna-Maria Belli, Antonio Coca, Michael Lee, Giuseppe Mancia, Jan H. Peregrin, Josep 
Redon, Jim A. Reekers, Costas Tsioufis, Dierk Vorwerk, and Roland E. Schmieder. 
72. 72. Chen PS, Tan AY. Autonomic nerve activity and atrial fibrillation. Heart Rhythm 2007;4(3 Supll):S61-S64.
73. 73. Arora R, Ulphani JS, Villuendas R, et al. Unique autonomic profile of the pulmonary veins and posterior left 
atrium. J Am Coll Cardiol 2007;49:1340-1348. 
74. 74. Wei Y, Xu J, Zhou G, Chen S, Ouyang P, Liu S. Renal Denervation Suppresses the Inducibility of Atrial Fibrillation 
in a Rabbit Model for Atrial Fibrosis. PLoS One. 2016 Aug 16;11(8):e0160634.]
75. 75. Yu L, Huang B, Wang Z et al. Impacts of Renal Sympathetic Activation on Atrial Fibrillation: The Potential Role of 
the Autonomic Cross Talk Between Kidney and Heart. J Am Heart Assoc. 2017 Mar 2;6(3). pii: e004716.]
76. 76. Coumel P, Attuel P, Lavallée J, Flammang D, Leclercq JF, Slama R. The atrial arrhythmia syndrome of vagal origin. 
Arch Mal Coeur Vaiss 1978;71:645–656. 
77. 77. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation 
pathophysiology and therapy. Circulation 2014;114:1500-1515. 
78. 78. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circulation 
research 2014;114:1004-1021.
79. 79. Arora R, Ulphani JS, Villuendas R, et al. Neural substrate for atrial fibrillation: implications for targeted 
parasympathetic blockade in the posterior left atrium. Am J Physiol Heart Circ Physiol. 2008;294:134-44.
80. 80. Linz D, Hohl M, Elliott AD et al. Modulation of renal sympathetic innervation: recent insights beyond blood 
pressure control. Clin Auton Res. 2018:28:375
24
RENAL SYMPATHETIC DENERVATION: RENAL NERVE STIMULATION 
1
25
RENAL SYMPATHETIC DENERVATION: RENAL NERVE STIMULATION 
1

P. Gal1, MD, M.R. de Jong1, MD, J.J.J. Smit1, MD PhD, A. Adiyaman1, MD, PhD, J.A. Staessen2, MD 
PhD, A. Elvan1, MD PhD
1  Department of Cardiology, Isala Klinieken, Zwolle, the Netherlands 
2 the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven 
Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
J Hum Hypertens. 2015 May;29(5):292-5
CHAPTER II
Blood pressure response to renal 
nerve stimulation in patients 
undergoing renal denervation: 
a feasibility study
Cardiovascular effects of renal nerve stimulation
ABSTRACT
During renal sympathetic denervation (RDN), no mapping of renal nerves is performed and 
there is no clear endpoint of RDN. We hypothesized high-frequency renal nerve stimulation 
(RNS) may increase blood pressure (BP), and this increase is significantly blunted after RDN. 
The aim of this study was to determine the feasibility of RNS in patients undergoing RDN. 
Eight patients with hypertension undergoing RDN were included. A quadripolar catheter was 
positioned at four different sites in either renal artery. RNS was performed during 1 minute 
with a pacing frequency of 20 Hz. Subsequently, all patients successfully underwent RDN. 
After RDN was performed, RNS was repeated at the site of maximum BP response before RDN 
in either renal artery. Mean age was 66 years. During RNS, BP increased significantly from 108 
/ 55 to 132 / 68 mmHg (P < 0.001). After RDN, systolic BP response at site of maximum response 
to RNS was significantly blunted (+43.1 mmHg vs. +9.3 mmHg, P = 0.002). In 25% of patients, a 
systolic BP increase > 15 mmHg after RDN. In conclusion, RNS resulted in an acute temporary 
increase in BP. This response was significantly blunted after RDN. RNS may potentially serve 
as an endpoint for RDN. 
Keywords: Renal denervation, renal nerve stimulation, therapy-resistant hypertension
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INTRODUCTION 
Endovascular renal sympathetic denervation (RDN) is a promising treatment modality in 
the treatment of resistant, essential hypertension.1, 2 Ablation lesions are rotationally and 
longitudinally applied in a spiral pattern to the renal artery to ablate the renal nerves under 
fluoroscopic guidance. However, no anatomical or functional mapping of renal nerves 
is performed during ablation. There is no functional test to guide RDN and no functional 
endpoint is defined to establish a successful RDN procedure. The potential therapeutic role 
of RDN in hypertensive patients is being questioned after announcement of failure of the 
Symplicity HTN-3 study to meet its primary efficacy endpoint.3 This suggests a modest overall 
effect of RDN and highlights the crucial need for a functional test to define a clear cut RDN 
procedural endpoint. Studies are needed to delineate the mechanisms of RDN and to optimize 
the technique before further deployment in patients. High-frequency renal nerve stimulation 
(RNS) in an animal model resulted in an acute temporary rise in blood pressure (BP), which 
was significantly blunted after RDN.4 However, no data is available on RNS in humans. The 
aim of this study was to design an RNS protocol and determine the effects of high-frequency 
electrical stimulation in the renal arteries on BP before and after RDN.
METHODS
Eight consecutive patients were included. Inclusion criteria were: office systolic BP exceeding 
140 mmHg and systolic BP on 24-hour ambulatory BP recording exceeding 130 mmHg, despite 
the use of at least three anti-hypertensive drugs, including at least one diuretic. Patients were 
excluded in case of secondary hypertension (e.g. hyperaldosteronism), or if a preprocedural 
CT scan revealed renal arteries that were not suitable for RDN. In case of dual renal arteries, 
RNS was performed in the renal artery with the largest diameter. 
The study was approved by the institutional review board and written informed consent 
was obtained from all patients. All procedures were performed under general anaesthesia, 
supervised by a cardiac anaesthesiologist.
RNS protocol 
A quadripolar catheter (EPXT, Bard, U.S.A.) was introduced in the renal artery via femoral 
access. The first renal artery to undergo RNS was alternated between left and right among 
patients. RNS was performed at four sites (distal – cranial, distal – caudal, proximal – cranial, 
proximal – caudal) in both arteries for 1 minute. Pacing frequency was set at 20 Hz4-7, pacing 
output at 20 mA and pulse duration at 2 ms. The pacing output setting was based on data in 
four patients (data not shown), in whom pacing output was gradually increased (5, 10, 15, 20 
mA respectively). BP response was only observed with a pacing output setting exceeding 10 mA, 
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and pacing output was set at twice the threshold. In the first four patients, RNS duration was 
set at 3 minutes. However, BP response was observed after 30 seconds in these patients (data 
not shown). Therefore, RNS duration was set at twice the threshold, thus at 1 minute. During 
RNS, vasoactive medication was not altered. Figure 1 displays a fluoroscopic image of the setup. 
Figure 1. Fluoroscopic image of renal nerve stimulation catheter setup. Panel A displays the renal angiogram. Panel 
B displays the quadripolar catheter, which has been inserted in the femoral artery, was maneuvered through the 
aorta and is positioned at the distal – caudal renal nerve stimulation site of the right renal artery.
Renal denervation protocol
The renal ablation catheter1, 2 (Symplicity, Medtronic, Minneapolis, MN, USA) was introduced 
into each renal artery via femoral access. Discrete, radiofrequency (RF) ablations lasting 
up to 2 minutes each and ≤8 Watts were applied, with up to six ablations within each renal 
artery, separated both longitudinally and rotationally under fluoroscopic guidance. During 
RF energy application, tip temperature and impedance were monitored. RF energy delivery 
was regulated by a predetermined algorithm. The results of RNS were not used during the 
ablation procedure.
Post ablation RNS protocol
After RDN was performed, the sites of maximum BP response in either renal artery were 
relocated, guided by fluoroscopy. RNS was performed at the same settings as before RDN, i.e. 
pacing frequency of 20 Hz, pacing output was set at 20 mA and pacing duration was set at 2 ms. 
RNS at the subsequent site was performed after the BP returned to its baseline value. 
Statistical analysis
Continuous variables were expressed as mean ± standard deviation or median with range 
where appropriate. Significances in differences were analyzed by a repeated measures 
analysis using mixed models. BP and heart rate response to RNS after RDN were compared to 
the BP and heart rate response at the corresponding site before RDN. Statistical analysis was 
performed using IBM SPSS statistics version 20 (IBM inc., Armonk, NY, USA). A P-value of ≤0.05 
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was considered statistically significant.
 
RESULTS
Eight consecutive patients were included, baseline characteristics are shown in Table 1. There 
was one patient with an accessory left renal artery and one patient with an accessory right 
renal artery. 
Table 1. Baseline characteristics
Age (years) 66.3 (±5.6)
Male gender (n) 5
Body mass index (kg m -2) 29.3 (± 1.3)
Systolic office (mm Hg) 172.3 (± 20.0)
Diastolic office BP (mm Hg) 96.1 (± 20.1)
24-h Ambulatory systolic BP (mm Hg) 153.3 (± 12.9)
24-h Ambulatory dialostic BP (mm Hg) 89.0 (± 3.5)
Antihypertensive drug use (range) 3.9 (3-6)
 ACE-inhibitors (n) 3
 Angiotensin II receptor blockers (n) 6
 Renin inhibitors(n) 1
 Beta blockers (n) 6
 Calcium channel blockers (n) 5
 Diuretics (n) 8
 Other (n) 2
Diabetes mellitus (n) 1
Serum creatinine (μmol l-1) 86.4 (± 15.7)
Abbreviations: ACE, angiotensin-converting enzyme; BP, blood pressure.
Data are presented as number of patients or mean ± s.d. or range where appropriate.
Blood pressure response to renal nerve stimulation
Mean BP increased during RNS from 107.6 (±13.0) / 54.5 (±7.4) mmHg before RNS to 132.3 (±25.0) 
/ 67.6 (±11.8) mmHg after RNS (P < 0.001), as displayed in Figure 2. At 19.2% of sites where RNS 
was performed, BP increase was 5 mmHg or less, which were distributed evenly among RNS 
sites. There were four patients who showed a BP increase exceeding 5mmHg at all RNS sites. 
The RNS sites that displayed the maximum BP increase were distributed evenly. 
Renal denervation
RDN was successfully performed in all patients, with a median of 5 ( range 4-6) RF applications 
per renal artery using the SymplicityTM catheter system. Mean catheter tip temperature was 
54.3 (±3.8) °C.
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Figure 2. Systolic blood pressure before and after renal nerve stimulation
This figure displays the systolic BP before and after RNS. Mean systolic BP increased from 107.6 (±13.0) mmHg to 132.3 
(±25.0) mmHg (P < 0.001) during RNS. The horizontal line indicates the mean systolic BP, the whiskers represent the 
range of systolic BP among patients. RNS: renal nerve stimulation; BP: blood pressure. See text for details.
Blood pressure response after renal denervation
BP response to RNS at the site of maximum response was +43.1 (±14.7) mmHg before RDN, 
compared to +9.3 (±10.5) mmHg after RDN, P = 0.002, as displayed in figure 3. In two patients at 
three sites, RNS after RDN increased systolic BP by more than 15 mmHg (15, 16 and 33 mmHg). 
Before RDN, RNS resulted in an increase of 42, 54 and 57 mmHg in systolic BP in these patients.
Figure 3. Systolic blood pressure response to renal nerve stimulation before and after renal denervation. RNS 
induced systolic BP increase at site of maximum response before renal nerve denervation (RDN) and after RDN. 
After RDN, systolic BP increase after RNS was significantly blunted: RNS induced systolic BP increase was +43.1 
(±14.7) mmHg before RDN compared to +9.3 (±10.5) after RDN, P = 0.002. The horizontal line indicates the mean 
systolic BP response during RNS, the whiskers represent the range of observed systolic BP responses among patients. 
RDN: renal denervation; RNS: renal nerve stimulation; BP: blood pressure. See text for details.
Heart rate response to renal nerve stimulation
2 patients were in atrial fibrillation during the procedure. The sinus cycle length shortened 
significantly during RNS from 1286.9 (±172.8) ms to 1069.2 (±274.0) (P < 0.001). After 
RDN, sinus cycle length shortening during RNS was significantly reduced (+210.7 ms vs. 
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44.7 ms, P = 0.015), as displayed in figure 4. Of note, maximum sinus length shortening 
after RDN was 152 ms. This patient also displayed a BP increase after RDN of 33 mmHg. 
Figure 4. Heart rate increase during renal nerve stimulation before and after renal denervation
This figure displays the sinus cycle length shortening during RNS before and after RDN. After RDN, the sinus cycle 
length shortening was significantly reduced compared to the sinus cycle length shortening before RDN (-210.7ms 
vs.-44.7 ms, P = 0.015). The horizontal line indicates the mean sinus cycle length reduction during RNS, the whiskers 
represent the range of observed sinus cycle length reductions among patients. RDN: renal denervation; RNS: renal 
nerve stimulation. 
DISCUSSION
This is, to our knowledge, the first clinical study in patients with resistant hypertension, 
showing that high-frequency RNS is feasible and results in an acute, temporary increase in 
BP. BP response was significantly blunted after RDN. RNS may be an important tool to assess 
successful RDN.
Blood pressure response to renal nerve stimulation
This study aimed to show the feasibility of RNS. We hypothesized stimulation of renal nerves 
produces an increased sympathetic nervous tone, resulting in an increase in blood pressure 
and heart rate. Earlier reports have shown stimulation of afferent sympathetic nerve increases 
vasoconstriction8-11 and induces metanephrine release11-14. Moreover, in a recent report4, RNS 
in an animal model was reported to produce an increase in BP and to induce epinephrine and 
norepinephrine release. 
Renal nerve anatomy
Atherton et al.15 showed, in a histologic study, 90% of renal nerves were located in the renal 
artery wall within the first 2 mm from the renal artery lumen, making them suitable for 
ablation. In the present study, we used high-frequency pacing to stimulate these renal nerves, 
resulting in an acute, temporary BP increase. Atherton et al. reported the number of nerves 
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tended to increase along the length of the renal artery. In the current study, the sites that 
displayed a BP increase less than 5 mmHg were evenly distributed among proximal and 
distal sites. However, our study was not designed to determine the association between the 
anatomical location of renal nerves data and the BP response to RNS. 
Non-responders to renal denervation
Recently, failure of the Symplicity HTN-3 study to meet its primary efficacy endpoint was 
announced and the results of this study will be presented at the ACC convention in March 
20143. This preliminary announcement suggests a modest overall effect of RDN and highlights 
the crucial need for a functional test to define a clear cut RDN procedural endpoint. 
Furthermore, the procedure needs optimization to allow reliable denervation of the renal 
arteries with reproducible clinical results. Studies are needed to delineate the mechanisms of 
RDN before further deployment of the technique. Previous studies demonstrated that about 
23% of patients did not show a BP reduction after RDN (non-responders)16. Hypothetically, a 
possible explanation is that not all renal nerves were successfully ablated during RDN. Since 
RDN is performed empirically, there is no clear cut functional endpoint to ascertain if all renal 
nerves have been successfully ablated. The present study showed RNS increased systolic BP 
after RDN in two patients. Potentially, ablation was incomplete in these patients, resulting in 
a BP increase up to 33 mmHg during RNS after RDN. Hypothetically, these patients are among 
the non-responders, although this feasibility study was not designed to prove this hypothesis. 
Potentially, RNS may be a technique to identify patients with incomplete ablation lesions and 
provide rationale for RNS guided application of additional ablation lesions to denervate the 
renal arteries. 
Future directions
In this study, RNS did not result in an acute BP rise in 19.2% of RNS sites. Hypothetically, the 
absence of BP response to RNS is indicative of local absence of sympathetic nerve fibers. 
Whether RNS can be used to map renal nerves and identify possible target sites for ablation, 
is yet to be delineated. 
The currently used catheter systems to perform RDN do not allow performing RNS. Potentially, 
a catheter system can be designed capable to both stimulate and ablate renal nerves, similarly 
to the currently used RF ablation systems that are used to perform cardiac ablations in 
patients with arrhythmias. 
Limitations
With regard to interpreting our data, the following limitations should be considered. This 
is a single center study with a limited number of patients. We did not use a 3D anatomical 
mapping system, since it was not available at the time of this study, RNS sites after RDN were 
identified using fluoroscopy. Patients were not followed up after RDN. 
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Conclusion
High-frequency electrical stimulation of nerves in the renal arteries results in a temporary 
increase in BP. RDN significantly blunted the BP response to RNS. Potentially, RNS can be used 
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CHAPTER III
Renal Nerve Stimulation-Induced 
Blood Pressure Changes Predict 
Ambulatory Blood Pressure 
Response after Renal Denervation
Creating an endpoint for renal nerve denervation
ABSTRACT
Blood pressure (BP) response to renal denervation (RDN) is highly variable and its effectiveness 
debated. A procedural endpoint for RDN may improve consistency of response. 
The objective of the current analysis was to look for the association between renal nerve 
stimulation (RNS)-induced BP increase before and after RDN, and changes in ambulatory 
blood pressure monitoring (ABPM) after RDN. 
Fourteen patients with drug-resistant hypertension referred for RDN were included. RNS 
was performed under general anaesthesia at four sites in the right and left renal arteries, 
both before and immediately after RDN. RNS-induced BP changes were monitored 
and correlated to changes in ambulatory BP at a follow-up of 3 to 6 months after RDN. 
RNS resulted in a systolic BP increase of 50±27 mmHg before RDN and systolic BP increase of 
13±16 mmHg after RDN (p<0.001). Average systolic ABPM was 153±11 mmHg prior to RDN and 
decreased to 137±10 mmHg at 3 to 6 months follow-up (p=0.003). Changes in RNS-induced BP 
increase before vs. immediately after RDN, and changes in ABPM before vs. 3 to 6 months after 
RDN were correlated, both for systolic BP (R=0.77, p=0.001) and diastolic BP (R=0.79, p=0.001). 
RNS-induced maximum BP increase before RDN had a correlation of R=0.61 (p=0.020) for 
systolic and R=0.71 (p=0.004) for diastolic ABPM changes.
RNS-induced BP changes before vs. after RDN were correlated with changes in 24-h ABPM 3-6 
months after RDN. RNS should be tested as an acute endpoint to assess the efficacy of RDN 
and predict BP response to RDN.
Keywords: sympathetic renal denervation, 24h ABPM, renal nerve stimulation, drug resistant 
hypertension
List of abbreviations
BP  Blood pressure
SBP  Systolic blood pressure
DBP  Diastolic blood pressure
RDN  Renal sympathetic denervation
ABPM  Ambulatory blood pressure monitoring
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INTRODUCTION
Renal sympathetic denervation (RDN) has been reported as a successful treatment of 
resistant hypertension in multiple trials studying the efficacy of RDN.1–6 The sham-controlled 
Symplicity HTN-3 trial, however, failed to show significant RDN induced changes in BP versus 
control,7 raising serious doubts about the efficacy of RDN.8–11 Variable effects of RDN on BP have 
been reported, with a wide spectrum ranging between non-response to marked reduction in 
BP.12 The absence of an ablation procedural endpoint for RDN is a potential explanation for 
variable responses and the successful implementation of a reliably predictable endpoint 
could improve procedural success and clinical response. 
Recently we reported on the feasibility of high frequency electrical renal nerve stimulation 
(RNS) in patients with resistant hypertension and demonstrated that RNS-induced BP 
increase was significantly blunted after RDN.13 We hypothesized that the difference between 
RNS-induced BP rise before and after RDN could be used as a procedural endpoint for RDN, 
and may prove a reliable functional test to predict BP response to RDN. The main goal of the 
current analysis was to investigate the 24-h ambulatory BP changes after RDN and the relation 
to RNS before and after RDN. 
METHODS
Patients
All patients with treatment-resistant hypertension referred for renal denervation between 
May 2014 and February 2015 were screened for inclusion in the RNS study. Patients were 
eligible if they were on a stable antihypertensive drug regimen of at least 3 antihypertensive 
drugs (preferably with a diuretic) for at least 1 month, guided by hypertension specialists. 
Office systolic BP was >140 or diastolic BP >90 mmHg and 24-h systolic BP was >130 or diastolic 
BP >80 mmHg despite stable treatment, excluding patients with white coat hypertension. 
Patients were screened for eligibility by a multi-disciplinary team, including cardiologists, 
hypertension specialists and a radiologist. All patients were willing and able to comply with 
the protocol and had provided written informed consent. Age range for possible inclusion 
was 18-80 years and glomerular filtration rate had to be >45 mL/min/1.73m2 according to the 
MDRD (Modification of Diet in Renal Disease) formula.14 
Exclusion criteria were an unsuitable anatomy for RDN assessed by CT-angiography (main 
renal artery lumen diameter ≤3 millimetre, or a total length <20 millimetre of the main 
arteries), type 1 diabetes mellitus, chronic oxygen use, primary pulmonary hypertension, 
pregnancy and a mental or physical inability to participate. Patients enrolled in another 
investigational drug or device study were also excluded. Secondary hypertension was 
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excluded by a rigorous protocol excluding hyperaldosteronism, pheochromocytoma, renal 
artery stenosis (>50% stenosis in one or both arteries on CT-angiography), drug or substance 
abuse induced hypertension when appropriate, according to the European guidelines for 
the management of hypertension.15 The study was approved by the local medical ethical 
committee (ABR number 47172) and was conducted according to the declaration of Helsinki. 
The trial is registered under ClinicalTrials.gov ID: NCT02496117.
Outcomes
The primary endpoints of the current study were invasively measured RNS-induced BP 
changes before and after RDN, the change in 24-h ABPM before RDN versus 3 to 6 months 
follow-up after RDN, and the correlation between these variables.1,14 Secondary endpoints 
were office BP measurements during follow up and number of antihypertensive drugs. To 
guard safety during RNS we set the maximum systolic BP during RNS at 180 mmHg, at which 
point RNS was immediately discontinued.
Procedures
RDN was performed under general anaesthesia. Throughout the RDN procedure, no changes 
were made in use of vasoactive medication and no inotropic medication was necessary. The 
procedure was performed by experienced cardiac electrophysiologists. Two sheaths were 
placed in the right femoral artery, one for continuous BP measurement and one for catheter 
access. 5000 IU of heparin were administered during the procedure. In addition, in patients 
not previously on acetylsalicylic acid, we administered 500 mg of acetylsalicylic acid. We 
performed angiography with a pigtail catheter to visualize the aorta and renal arteries. 
Initially, a conventional quadripolar catheter with a tip electrode of 2 mm, other electrodes 
of 1 mm and interelectrode spacing of 5 mm (EP-XT, C. R. Bard, Inc., Murray Hill, NJ, USA) 
was introduced in the renal artery, under fluoroscopic guidance. Unipolar stimulation 
was performed from the tip of the catheter. This catheter was used only when performing 
RDN with the single-electrode ablation catheter (Symplicity Flex Renal Denervation 
Catheter, Medtronic, Minneapolis, MN, USA). In patients who were ablated with the multi-
electrode basket ablation catheter (EnligHTN, St Jude Medical, Saint Paul, MN, USA), bipolar 
stimulation was performed by the ablation catheter itself, with bipolar stimulation from 
poles 1-2 and 3-4 proximally and distally in the renal artery. The first renal artery to undergo 
RNS was alternated between left and right among consecutive patients. RNS was performed 
at multiple sites with a minimum of 4 sites in both arteries, ensuring that different quadrants 
of the arterial circumference were stimulated in proximal and distal areas of the renal artery, 
in which ablations were usually performed. Pacing frequency was set at 20 Hz, pacing output 
at 20 mA with a pulse duration of 2 ms, based on earlier research.13,16–19 Stimulation duration 
was 60 sec, or shorter when systolic BP increased beyond 180 mmHg. We waited for the BP to 
return to baseline values before proceeding to the next stimulation site. 
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After RNS in both arteries (total of at least 8 stimulation sites), we performed a standard RDN 
procedure. The single-electrode Medtronic renal ablation catheter was used in 3 patients and 
the St. Jude multi-electrode EnligHTN catheter in 11 patients. In one patient, a combination of 
both single electrode and multi-electrode RDN catheters was used. In this latter patient, the 
left renal artery was denervated with the multi-electrode basket catheter. We switched to the 
flexible single electrode catheter due to anatomical variation prohibiting the introduction of 
the multi-electrode basket catheter in the right renal artery. The use of the single electrode 
catheter (Symplicity, Medtronic) has been described previously.13 The multi-electrode RDN 
catheter contains 4 electrodes separated from each other in a basket configuration. Up to 4 
discrete radiofrequency (RF) ablations were applied simultaneously, each application lasting 
up to 120 seconds with a power ≤8 Watts (W) and a target temperature of 70 degrees Celsius 
(158 degrees Fahrenheit). Electrodes that did not reach the target temperature or impedance 
drop were switched off. In each renal artery, up to 3 sets corresponding to 12 ablation points 
were performed, separated both longitudinally and rotationally under fluoroscopic guidance. 
During RF energy application, tip temperature and impedance were monitored. RDN was 
considered successful when the maximum number of anatomically possible ablation points 
was reached, in accordance with standard care. 
Importantly, the results of RNS were only monitored and did not influence the number 
of RF applications or the RDN procedure. After RDN we repeated the RNS procedure, 
fluoroscopically placing the pacing electrodes at the site at which the maximum BP response 
to RNS was observed prior to RDN. We chose to check the site of maximum BP response to 
ensure that the difference between patients that still showed an increase in BP after RDN and 
patients that no longer showed an increase in BP in response to RNS would become clear. 
The Bard EP system (Labsystem Pro, Bard, USA) was used to record and monitor BP changes 
throughout the procedure. Additionally we documented all RNS-related BP changes on a 
study work list. 
Patients were followed and monitored as an outpatient by a vascular internist, who was 
informed that RDN was successfully performed, but was unaware of the results of the RNS. 
In all patients a validated 24-h ABPM with 30 min BP measuring intervals was obtained 
(Spacelabs, Snoqualmie, WA, USA) at 3 and/or 6 months after the procedure to assess the effect 
of RDN.20 Office BP measurements were executed either by repeated automated oscillometry 
measurements (intrinsically blinded) or by sphygmomanometry during outpatient contacts. 
BP measurements by sphygmomanometry were performed by technicians not involved in 
analysis of the study and were regarded blinded. Antihypertensive drug therapy was left 
unchanged, unless symptomatic hypotension or out of range hypertension (>180 mmHg 
systolic BP) warranting immediate control were present. 
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Statistical analysis
Categorical variables were summarized by frequencies and percentages. Continuous variables 
(i.e. ABPM, office systolic BP, office DBP) are reported as mean and standard deviation or 
median and interquartile range where appropriate. Variables were tested for normality of 
distribution. A paired t-test was used to compare continuous variables, Wilcoxon signed rank 
test was applied to compare the difference in number of antihypertensive drugs. Pearson’s 
correlation was used to assess the relation of RNS-induced BP changes assessed by office BP and 
24-h BP measurements. To compare the different correlations, a Fisher’s R to Z transformation 
was used. Statistical analysis was performed using IBM SPSS statistics version 20 (IBM Inc. 
Armonk, NY, USA). A P-value of ≤0·05 was considered statistically significant. 
RESULTS
Demographics
Fourteen patients were included in the RNS study. Patients underwent their RDN procedure 
between May 2014 and February 2015. The demographic and clinical characteristics at baseline 
are shown in Table 1. The anatomy of the renal vasculature is represented by the Okada 
classification. 
Table 1. Baseline characteristics (n=14 patients)
Variable Baseline Follow up (3 to 6 months) P-value
Age (years) 66 [39-76] - -
Male gender 7/14 - -
Office systolic BP (mmHg) 166 ± 23 149 ± 19 0.003 
Office diastolic BP (mmHg) 98 ± 14 90 ± 15 0.017 
24-h systolic ABPM (mmHg) 153 ± 11 137 ± 10 0.003 
24-h diastolic ABPM (mmHg) 88 ± 8 80 ± 9 0.018 
Hypercholesterolemia 10/14
BMI (kg/m²) 29.2 ± 2,9 - -
Creatinine (µmol/L) 84 ± 16 86 ±17 0.570




Diabetes mellitus type II 1/14
Heart rate (bpm) 66 ± 8 66 ± 7 0.716
# anti-hypertensive drugs 4 [3-6] 4 [2-6] 0.206
•	 diuretic 9/14 8/14
•	 ARB 13/14 13/14
•	 ACEi 1/14 1/14
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Table 1 continued.
Variable Baseline Follow up (3 to 6 months) P-value
# anti-hypertensive drugs
•	 β blocker 9/14 10/14
•	 CCB 12/14 10/14
•	 α1 blocker 6/14 4/14
•	 renin inhibitor 1/14 1/14
•	 aldosterone antagonist 6/14 5/14














Values between brackets indicate range, other values represent standard deviation, BP = blood pressure, ABPM = ambulatory blood 
pressure monitoring, BMI = body mass index, GFR = glomerular filtration rate, MDRD = modification of diet in renal diseases, CAD 
= coronary artery disease, ARB = angiotensin receptor blocker, ACEi = angiotensin converting enzyme inhibitor, β blocker = beta 
receptor blocker, CCB = calcium channel blocker, α1 blocker = α1 receptor blocker, CAS = centrally acting sympatholytic
Procedural data
In all 14 patients denervation of the renal arteries was performed. The median number of 
ablations was 8 in both arteries. The number of RF ablations ranged from 4 to 16 in the right 
renal artery and from 4 to 12 in the left renal artery. Six out of the 14 patients had accessory 
renal arteries. Details of renal vasculature based on the Okada classification are summarized in 
Table 1. The accessory arteries were deemed too small for additional denervation. Depending 
on the RDN system used, RF energy was delivered based on tip temperature or impedance 
drop. EnligHTN multi-electrode RDN system (St Jude Medical) simultaneously delivers RF 
energy at 4 electrodes of the basket catheter in a temperature controlled mode with a target 
70 degrees Celsius (158 degrees Fahrenheit). In patients denervated with the Symplicity RDN 
system, RF energy delivery is fully automated and the system displays changes in impedance 
during RF energy application. An impedance drop of >10% was considered successful. If 
target ablation point did not reach adequate impedance drop or target temperature, the RF 
application was automatically turned off. Delivered RF energy ranged from 2.0 W to 6.6 W and 
was not allowed to exceed 8.0 W. 
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Of the cumulative 105 sites that were successfully stimulated, an increase in systolic BP of 
more than 10 mmHg in response to RNS was elicited at 78 sites (74.3%). Procedural data on 
the RNS sites is summarized in Table 2. Of note, in one patient no RNS has been performed 
in the right renal artery due to technical failure of the stimulator (Micropace). Response to 
RNS varied between patients with a median number of responding sites of 4.5, ranging from 
3 to 12 RNS sites per patient. In the responding patients increases ranged from no response to 
a systolic BP increase of 118 mmHg. In one patient we observed no increase in BP exceeding 10 
mmHg. In this patient, SBP increases ranged from no response to 9 mmHg increase in BP. We 
observed a preference for the site of maximum response to be in the upper quadrants, both 
distally and proximally (22/27 vs. 5/27 locations, p=0.001). No clear differences were observed 
between the right en left renal artery. There were no complications.
Table 2. Procedural data (n=14 patients)




# sites with SBP increase >10 mmHg 41 (76%) 37 (73%)
# sites with no BP response to RNS 13 (24%) 14 (27%)
Site of maximum SBP response to RNS N = 14 arteries N = 13 arteries
Distal lower quadrant 7/14 (50.0%) 6/13 (46.2%)
Distal upper quadrant 0/14 (0.0%) 0/13 (0.0%)
Proximal lower quadrant 4/14 (28.6%) 4/13 (30.8%)
Proximal upper quadrant 2/14 (14.3%) 2/13 (15.4%)
Mid renal roof 0/14 (0.0%) 1/13 (7.7%)
Mid renal bottom 1/14 (7.1%) 0/13 (0.0%)
# RF ablation points 8 [4-12] 8 [4-16]
Table 2 summarizes the procedural data of the patients. In one patient no RNS was performed in the right renal artery due to 
technical failure of the stimulator (Micropace). No significant differences between the left and right renal arteries were observed. 
In agreement with our previous work,13 the mean increase in systolic BP in response to RNS at 
the site of maximum response significantly decreased from 50 ± 27 mmHg before RDN to 13 ± 
16 mmHg after RDN (p<0.001). See Figure 1 for a visual depiction of the data.
At a median follow-up of 4.5 months (3-6 months), office SBP decreased from 166 ± 23 mmHg 
at baseline to 149 ± 19 mmHg (p=0.003). DBP decreased from 98 ± 14 mmHg to 90 ± 15 mmHg 
during follow-up. At the same time point, 24-h systolic BP decreased from 153 ± 11 mmHg at 
baseline to 137 ± 10 mmHg (p=0.003). Antihypertensive drugs were increased in 2 patients and 
decreased due to symptomatic hypotension in 5 patients. However, the median number of 
anti-hypertensive drugs remained unchanged. 
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Figure 1. The maximum increase in systolic BP before the RDN procedure was 50 ± 27 mmHg and decreased to 13 ± 
16 mmHg after the RDN procedure (p<0.001).
Changes in ABPM systolic BP documented at median follow-up of 4.5 months after RDN were 
correlated with RNS-induced systolic BP rise before RDN at the site of maximum response 
(R=0.610, p=0.020). This correlation further increased after subtracting the RNS-induced BP 
rise measured immediately after RDN (DBP at site of maximal response=RNS induced BP 
increase prior to RDN-RNS induced BP increase after RDN) at the same site (R=0.769, p=0.001). 
These findings hold true for DBP as well (see Figure 2). Changes in 24-h ambulatory DBP were 
strongly correlated with RNS-induced DBP rise before RDN at the site of maximum response 
(R=0.734, p=0.003). In contrast, no significant correlation was observed between ABPM BP 
changes after RDN and residual RNS-induced BP rise after RDN considered alone.
Figure 2. The Pearson’s correlation between the difference in systolic blood pressure increase induced by renal 
nerve stimulation before versus immediately after renal denervation, and the difference in mean 24-h systolic 
pressure before versus 3 to 6 months after renal denervation was R= 0.769 (p=0.001, left upper quadrant). The 
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Pearson’s correlation between the initial RNS-induced increase in systolic blood pressure prior to RDN procedure 
and the difference in mean 24-h systolic blood pressure was R=0.610 (p=0.020, right upper quadrant). The Pearson’s 
correlation between the difference in diastolic blood pressure increase induced by renal nerve stimulation before 
versus after renal denervation, and the difference in mean 24-h diastolic pressure at a median of 4·5 months of 
follow-up was R=0.664 (p=0.010, left lower quadrant). The Pearson’s correlation between the initial RNS-induced 
increase in diastolic blood pressure prior to RDN procedure and the difference in mean 24-h diastolic blood pressure 
was R=0.734 (p=0.003). 
Changes in office BP were correlated with the acute BP data during the procedure. The 
difference in systolic BP increase before versus after RDN was significantly correlated with the 
clinical outcome based on office systolic BP (R=0.724, p=0.003). The difference in DBP increase 
before versus after RDN was significantly correlated with office DBP outcome during follow-
up (R=0.539, p=0.047). See Figure 3 for depiction of the data. However initial RNS induced BP 
increase before RDN was not correlated with the DBP outcome. The increase in BP after RDN 
was not correlated with office BP data during follow-up.
Figure 3. The Pearson’s correlation between the difference in systolic blood pressure increase induced by renal nerve 
stimulation before versus immediately after renal denervation, and the difference in office systolic pressure before 
versus 3 to 6 months after renal denervation was R= 0.724 (p=0.003, left upper quadrant). The Pearson’s correlation 
between the initial RNS-induced increase in systolic blood pressure prior to RDN procedure and the difference in 
office blood pressure was R=0.446 (p=0.110, right upper quadrant). The Pearson’s correlation between the difference 
in diastolic blood pressure increase induced by renal nerve stimulation before versus after renal denervation, and 
the difference in office diastolic pressure at a median of 4·5 months of follow-up was R=0.539 (p=0.047, left lower 
quadrant). The Pearson’s correlation between the initial RNS-induced increase in diastolic blood pressure prior to 
RDN procedure and the difference in office diastolic blood pressure was R=0.238 (p=0.412).
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DISCUSSION
In this study, we have demonstrated that high frequency RNS before and after RDN is feasible 
and safe in patients. In addition, it is suggested that the use of RNS may facilitate prediction of 
the completeness of RDN and subsequent BP changes after the procedure.13 The current work 
describes for the first time the significant association between RNS-induced BP responses 
during RDN, and the clinical ABPM response to RDN at 3 to 6 months after RDN. This reflects 
the potential of using RNS as a functional test to evaluate the efficacy of renal nerve ablation 
and predict the clinical outcome of the RDN procedure.
Since the publication of the Symplicity HTN-3 trial,21 a study that failed to demonstrate BP 
reduction above and beyond a sham procedure, RDN has been the topic of renewed and 
ongoing debate. Some have questioned the efficacy of RDN, and others sought reasons for 
the negative findings. It has been argued that the poor efficacy of RDN in Symplicity HTN-
3 may be partly explained by suboptimal renal nerve ablation.10 In contrast, in the recent 
DENERHTN trial,6 RDN was performed by a limited number of experienced operators, and 
drug adjustment was fully standardized, with a moderate but significant overall benefit of 
RDN on daytime ABPM. A recent meta-analysis by Fadl Elmula and colleagues including all 
published randomised controlled trials testing RDN against stable or intensified medical 
treatment showed little if any benefit of RDN.22 The troubling implication is that the BP benefit 
directly assignable to RDN may have been substantially overestimated in Symplicity HTN-1 
and 2 and other non-randomised unblinded studies using office BP as primary endpoint.3–5 
RDN is supported by a solid rationale, including reports from the years 1940-6023-26. During 
those times radical surgery was performed for sympathetic denervation, successfully lowering 
blood pressure, however, also in these patients a percentage appeared to be non-responders. 
High frequency electrical stimulation of the sympathoexcitatory renal afferent pathways is 
the most likely cause of the rise in BP induced by RNS. This is because the gradual rise in 
BP 10-20 sec after starting RNS is consistent with an increase in adrenergic response through 
stellate ganglion stimulation in canine studies as reported previously.27 Experimental studies 
indicate that the afferent nerves play an important role in the sudden increase in BP in 
response to RNS.28,29 The afferent nerves are involved in the increase of central sympathetic 
tone. Peripheral renal denervation has a peripheral sympatholytic effect and alters the level 
of activation excitation of central noradrenergic pathways but does not alter sodium or water 
intake or excretion, plasma renin activity or creatinine clearance, suggesting that efferent 
renal nerve function does not play an important role in the maintenance of this form of 
hypertension. Selective lesioning of the renal afferent nerves attenuates the development of 
hypertension, thus providing direct evidence that the renal afferent nerves, at least in part, 
participate in the pathogenesis of renovascular hypertension.30 Therefore, RNS influences 
this BP regulating mechanism by increasing the central sympathetic tone through an afferent 
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mechanism. The efferent nerve fibres would take more time to increase BP and renal artery 
vasoconstriction alone cannot explain a transient increase in BP in the femoral artery where 
BP was measured. We believe that the increase in central sympathetic tone accounts for an 
increase in systemic vascular resistance. One might argue that pain sensation invokes the 
increase in BP, but we did not observe an increase in the level of consciousness which would 
be expected when pain sensation increased greatly. All of the procedures were performed 
supervised by a cardiac anaesthesiologist, ensuring that pain was prevented. This study 
demonstrates a relationship between the increase in BP before vs. after a RDN procedure 
and the decrease in 24-h ambulatory BP. It is very unlikely that this can be an effect of the 
ablation of pain fibres surrounding the renal arteries. RNS enables the operator to determine 
the location of the renal nervous fibers, in which both afferent and efferent fibers are located. 
Both are to be targeted during a RDN procedure to diminish hypertension. Differences in 
BP increase are attributed to the differences in distribution of sympathetic nerve fibers in 
the tunica adventitia of the renal artery. The between-patient differences herein account for 
differences in response to high frequency electrical stimulation. 
Failure to improve BP after RDN may reflect a poor contribution of the renal nerve sympathetic 
system to the pathophysiology of hypertension in a particular patient, or alternatively failure 
to ablate a sufficient proportion of sympathetic fibers.31 Unfortunately, so far, RDN has been 
performed unguided, mostly using unipolar electrodes, in the absence of a straightforward 
method allowing quantification of the renal sympathetic traffic before RDN and assessment 
of the completeness of renal nerve ablation after RDN. We hypothesized that peri-procedural 
high frequency RNS could be an attractive candidate to address both issues. One heavily 
criticized RDN study in the treatment of AF has used this modality to in the setting of catheter 
ablation in patients with atrial fibrillation and hypertension.32 While acute RNS-induced 
BP rise before RDN may reflect the contribution of renal sympathetic nervous system, the 
difference between RNS-induced BP rise before and after RDN may be a reliable indicator of 
the efficacy of the RDN procedure. The patient that did not show an increase in BP exceeding 
10 mmHg in response to RNS at any point was a non-responder with office BP unchanged. This 
could theoretically be predicted by RNS since no sympathetic overdrive was observed prior 
to RDN. More importantly, patients that do show an impressive increase in BP before RDN 
and still do after RDN might require more extensive ablation. However, this has not been 
addressed in this explorative study. 
Notably, RNS-induced BP changes were better correlated with ambulatory than with office BP, 
enforcing our belief that “true” responders to RDN are those defined according to ambulatory 
BP, which should be used as primary criterion both for patient selection and evaluation of 
efficacy.33 The fact that office BP measurements have not been carried out as standardized as 
the 24-h ABPM may have played a part as well, leading to overestimation of the effect of white 
coat hypertension during office measurements.
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Our results are in line with the pioneering experimental study of unilateral RDN in dogs 
by Chinushi and his colleagues.16 However, to the best of our knowledge, we are the first 
to describe this electrical stimulation-guided renal nerve mapping technique along with 
clinical outcome in patients with resistant hypertension. 
The presence of an accessory artery might be another explanation why patients fail to respond 
to regular RDN. Previous reports showed significantly lower BP reduction in patients with 
accessory arteries that could not be denervated because of small size (<3-4 mm in diameter).34 
Because the sympathetic plexus is complex, when the accessory renal artery originates far from 
the main renal artery, an extra plexus may accompany the accessory artery. The remaining 
nerve tissue may lead to a possible sympathetic response via this pathway.35 
Admittedly, our study has limitations. First, the sample size is small. Secondly, our study is 
unblinded and purely observational, and the results may have been obscured by various 
patient- and physician-related biases. However, the impact of white coat effect was limited by 
the use of 24-h ambulatory blood pressure, and other potential confounders such as changes 
in drug adherence have been closely monitored. Finally, although we tried to perform RNS 
in several quadrants proximally and distally in the renal artery, we cannot exclude that 
some renal nerves were not stimulated, possibly decreasing the association between RNS 
and clinical response to RDN. In experimental studies norepinephrine spill over has been 
measured to assess efficacy of RDN. A suggestion for future research would be to correlate 
our findings with norepinephrine spill over or other ways to estimate sympathetic overdrive. 
In conclusion, this study demonstrates that the difference between acute RNS-induced BP rise 
before and after RDN is a significant predictor of BP outcome after RDN, probably because 
it conveys information on two major determinants of BP response to RDN: the importance 
of renal sympathetic activity at baseline and the completeness of renal nerve ablation after 
RDN. Future research should aim to demonstrate whether RNS-guided ablation - performed 
with the goal to decrease as much as possible RNS-induced BP response - allows the procedure 
to achieve more important and consistent BP decreases than conventional RDN.
Perspectives
Competency in medical knowledge: this study demonstrates that the difference between 
acute RNS-induced BP rise before and after RDN is a significant predictor of BP outcome after 
RDN, probably because it conveys information on two major determinants of BP response to 
RDN: the importance of renal sympathetic activity at baseline and the completeness of renal 
nerve ablation after RDN.
Competency in procedural skills: renal nerve stimulation (RNS) may be used as a functional 
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Translational outlook
Future research should aim to demonstrate whether RNS-guided ablation - performed with 
the goal to decrease as much as possible RNS-induced BP response - allows the procedure to 
achieve more important and consistent BP decreases than conventional RDN. This would 
change the procedural approach radically.
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ABSTRACT
Blood pressure response to renal denervation is highly variable and the proportion of 
responders is disappointing. This may be partly due to accessory renal arteries too small for 
denervation, causing incomplete ablation. Renal nerve stimulation before and after renal 
denervation is a promising approach to assess completeness of renal denervation and may 
predict blood pressure response to renal denervation.
The objective of the current study was to assess renal nerve stimulation-induced blood 
pressure increase before and after RDN in main and accessory renal arteries of anaesthetized 
patients with drug-resistant hypertension. The study included 21 patients. Nine patients had 
at least one accessory renal artery in which renal denervation was not feasible. Renal nerve 
stimulation was performed in the main arteries of all patients and in accessory renal arteries 
of 6/9 patients with accessory arteries, both before and after RDN. 
Renal nerve stimulation before renal denervation elicited a substantial increase in systolic 
blood pressure, both in main (25.6 mmHg±2.9 mmHg, p<0.001) and accessory (24.3±7.4 
mmHg, p=0.047) renal arteries. After renal denervation, renal nerve stimulation-induced 
systolic blood pressure increase was blunted in the main renal arteries (DSBP 8.6 mmHg±3.7 
mmHg, p=0.020) but not in the non-denervated renal accessory renal arteries (DSBP 27.1±7.6 
mmHg, p=0.917). 
Renal nerve stimulation-induced blood pressure increase after renal denervation of main 
renal arteries was significantly blunted in main renal arteries but not in accessory renal 
arteries. This residual source of renal sympathetic tone may result in persistent hypertension 
after ablation and partly account for the large response variability.
Keywords: renal sympathetic denervation, renal nerve stimulation, accessory artery, therapy-
resistant hypertension
List of abbreviations
BP  Blood pressure
SBP  Systolic blood pressure
DBP  Diastolic blood pressure
RDN  Renal sympathetic denervation
ABPM  Ambulatory blood pressure monitoring
RNS  Renal nerve stimulation
RF  Radio-frequency
ABR  Algemene beoordeling en registratie (Dutch study registration)
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INTRODUCTION
Renal sympathetic denervation (RDN) has been accepted as a treatment for resistant 
hypertension 1,2 because of the promising first results.3-5 However, failure of the RDN to lower 
blood pressure over and above the sham control group in the large randomised double-
blinded Symplicity HTN-3 trial 6 has raised doubt about the efficacy of the technique.7 Besides 
crucial design differences between Symplicity HTN-3 and previous, unblinded and mostly 
observational studies,8 the disappointing results of Symplicity HTN-3 may have been partly 
due to insufficient renal ablation.9,10 The possible role of insufficient renal ablation is further 
highlighted by the demonstration of a lesser response to RDN in patients with multiple 11 and 
accessory 12 renal arteries, which may contribute to the large variability of response observed 
after RDN.13 However, the mechanisms underlying these clinical observations have not yet 
been elucidated.14
Recently we showed that blood pressure increase elicited by high-frequency renal nerve 
stimulation (RNS) is significantly blunted after RDN.15 This approach may allow to gain 
further insights into the differences in blood pressure response to RDN in patient with or 
without renal accessory arteries. We hypothesized that after successful RDN there will be no 
significant increase in blood pressure after RNS in the main arteries while there will still be 
an increase in blood pressure in response to RNS in the accessory arteries. In order to test 
our hypothesis we investigated the blood pressure response to RNS in patients with only two 
renal arteries, as well as in patients with accessory renal arteries too small for renal nerve 
ablation, both before and after RDN of the main renal arteries. 
METHODS
Primary objective
The main goal of this clinical study was to investigate the blood pressure response to high 
frequency electrical stimulation in accessory renal arteries before and after denervation of 
the main renal arteries in patients with resistant hypertension.
Study design
We performed a prospective single-center intervention study.
Patient population, inclusion and exclusion criteria
All patients between May 2014 and February 2015 with treatment-resistant hypertension 
referred for renal denervation were screened for inclusion in the renal nerve stimulation 
(RNS) study. Patients were eligible if they were on a stable antihypertensive drug regimen 
of at least 3 antihypertensive drugs (preferably with a diuretic) for at least 1 month, guided 
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by experienced physicians in hypertension treatment. Office SBP should be >140 or DBP 
>90 mmHg and 24-h ABPM SBP should be >130 or DBP >80 mmHg despite stable treatment, 
excluding patients with white coat hypertension. Patients were screened for eligibility by a 
multi-disciplinary team, including cardiologists, internists with hypertension subspecialty 
and a radiologist. All patients were willing and able to comply with the protocol and had 
provided written informed consent. Age range for possible inclusion was 18-80 years and 
glomerular filtration rate had to be >45 mL/min/1·73m2 according to the MDRD formula. 
Exclusion criteria were an unsuitable anatomy for RDN assessed by CT-angiography (main 
renal artery lumen diameter ≤3 millimeter, or a total length of less than 20 millimeter 
of the main arteries), type 1 diabetes mellitus, chronic oxygen use, primary pulmonary 
hypertension, pregnancy and a mental or physical inability to participate. Patients enrolled in 
another investigational drug or device study were also excluded. Secondary hypertension was 
excluded by a rigorous protocol excluding hyperaldosteronism, pheochromocytoma, renal 
artery stenosis (>50% stenosis in one or both arteries on CT-angiography), drug or substance 
use induced hypertension when appropriate, according to the European guidelines for the 
treatment of hypertension.16 The study was approved by the local medical ethical committee 
(ABR number 47172) and was conducted according to the declaration of Helsinki.
Endpoints
The primary end points of our study were twofold. The first endpoint was the difference 
between blood pressure response to RNS applied in accessory renal arteries before and after 
RDN, based on the intra-arterially measured blood pressure one minute after RNS-application. 
In daily routine this concerns accessory arteries with a lumen diameter of 3 millimeter or less. 
The second endpoint was the response in arterial blood pressure to RNS before and after RDN 
in the main renal arteries.
Procedure
In all patients, RDN and RNS were performed under general anesthesia with propofol 
administered intravenously, accompanied by fentanyl to reduce possible pain sensation. 
The administration of epinephrine was indicated only in case of severe hypotension, which 
proved to be unnecessary. No other medication acting on blood pressure or on vascular tone 
were administered during the procedure. Two sheaths were placed in the right femoral artery, 
one for continuous BP measurement and one for catheter access. 5000 IU of heparin were 
administered during the procedure. In addition, in patients not previously on acetylsalicylic 
acid, we administered 500 mg of acetylsalicylic acid intravenously.
The RNS protocol has been described in detail previously.15 Briefly, a quadripolar catheter 
(EPXT, Bard, Murray Hill, NJ, USA) was introduced in the renal artery via femoral access. The 
first renal artery to undergo RNS was alternated between left and right among patients. RNS 
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was performed at four sites (distal – cranial, distal – caudal, proximal – cranial, proximal – 
caudal) in both arteries for 1 minute. Pacing frequency was set at 20 Hz, pacing output at 20 
mA and pulse duration at 3 ms. This protocol was established in our earlier research.15 To assess 
blood pressure response to RNS in the accessory artery, the same quadripolar catheter (EPXT, 
Bard, USA) was introduced in the accessory renal artery under fluoroscopic guidance. RNS was 
performed ostially in the accessory renal artery for 1 minute. The intra-arterially measured BP 
was determined immediately after cessation of RNS which was administered for one minute, 
or less in the case of severe BP increase with systolic BP reaching values that would exceed the 
maximum limit of 180 mmHg.
The renal ablation catheter by Medtronic (Symplicity, Medtronic, Minneapolis, MN, USA) 
was used in 12 patients and later the catheter by St. Jude Medical (EnligHTN, St. Jude Medical, 
Saint Paul, MN, USA) in 9 patients. The RDN catheter was introduced into each renal artery 
via femoral access. The use of the single electrode catheter (Symplicity, Medtronic) has 
been described previously.15 The multi-electrode RDN (EnligHTN, St Jude Medical) catheter 
contains 4 electrodes separated from each other in a basket configuration. Up to 4 discrete 
radiofrequency (RF) ablations were applied simultaneously, each application lasting up to 
120 seconds and ≤8 Watts with a target temperature of 70 degrees Celsius. Electrodes that did 
not reach the target temperature or impedance drop were switched off. In each renal artery, 
up to 12 ablations were produced, separated both longitudinally and rotationally under 
fluoroscopic guidance. During RF energy application, tip temperature and impedance were 
monitored. The results of RNS were only monitored and did not influence the number of RF 
applications. Figure 1 displays a typical example of a fluoroscopic image of the aorta, main 
renal arteries and an accessory renal artery that was not suitable for RDN, but eligible for RNS. 
RDN of these relatively small accessory renal arteries (diameter <3 mm) was not possible 
with the currently available catheters. Therefore, RDN in the accessory renal artery was 
not performed. After the RDN procedure of the main renal arteries, RNS in the main renal 
arteries was repeated according to the same stimulation protocol. Then a standard steerable 
quadripolar catheter (EPXT, Bard Electrophysiology) was placed in the accessory renal artery 
under fluoroscopic guidance. Once the quadripolar catheter was inserted in the accessory 
renal artery, RNS was performed with the same settings as for the other RNS locations. Blood 
pressure was recorded continuously during RNS.
Statistical analysis
All results are shown for the whole group and the subsets with and without accessory renal 
arteries. Categorical variables are summarized by frequencies and percentages. Continuous 
variables (i.e. ABPM, office SBP, office DBP) are reported as mean and standard deviation or 
median and interquartile range where appropriate. Variables were tested for normality of 
distribution. Main study endpoint was the arterial blood pressure response to RNS prior to 
RDN and decrease or absence of blood pressure increase in response to pacing in the renal 
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artery after RDN. The decrease or absence of blood pressure increase in response to pacing 
was defined as no or minimal blood response increase (<10 mmHg systolic blood pressure) in 
response to RNS. The percentage of patients without blood pressure increase are presented. 
Responses to RNS at the site of maximal response were taken into account in the analysis. 
Statistical analysis was performed using IBM SPSS statistics version 20 (IBM inc., Armonk, NY, 
USA). A P-value of ≤0.05 was considered statistically significant. 
RESULTS
Our study included 21 patients with resistant hypertension who underwent RDN, either using 
the Symplicity RDN catheter (Medtronic, n=12), or the EnligHTN catheter (St. Jude Medical, 
n=9). 9/21 patients had an accessory artery deemed too small for denervation (diameter <3 
mm, A2 or A3 subtype according to the Okada classification).17 Of these 9 accessory arteries 6 
could be reached with the smaller size standard quadripolar stimulation catheter and RNS 
was performed in those 6 patients. RNS was performed both before and after RDN in all main 
renal arteries, as well as in non-denervated accessory arteries in which this proved feasible 
using the smaller size standard quadripolar stimulation catheter. 
The demographic and clinical characteristics, renal anatomy, blood pressure level and 
antihypertensive treatment at baseline are shown in table 1, both for the whole group and 
in patients with or without renal accessory arteries. No significant difference was observed 
between both groups, with the exception of daytime systolic blood pressure, which was 
higher in the accessory renal artery group. A fluoroscopic image showing a set of main renal 
arteries and one accessory renal artery is displayed in figure 1. 
Table 1. Baseline characteristics 
Characteristic All patients
(n = 21)
Patients without accessory  
renal artery  
(n = 12)
Patients with accessory  
renal artery 
(n = 9)
Age (years) 64 (± 6) 63 (± 6) 65 (± 7)
Sex 
   Males   15 (71.4%) 8 (66.7%)
 
7 (77.8%)
Body-mass index (kg/m2) 29.6 (± 3.1) 29.5 (± 3.1) 29.6 (± 3.3)
Current smokers 1 (4.8%) 1 (8.3%) 0 (0%)
Medical history 
   Hypercholesterolemia 
   Type 2 diabetes mellitus 
   Coronary artery disease














Number of antihypertensive medications 4 [2 – 6] 4 [3 – 6] 4 [2-5]
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Patients without accessory  
renal artery  
(n = 12)
Patients with accessory  
renal artery 
(n = 9)
Class of antihypertensive medication
   Diuretic
   Aldosterone receptor blocker
   Beta-blocker
   Calcium channel blocker
   ACE- inhibitor
   Angiotensin receptor blocker
   Aliskiren
   Centrally acting α2-sympatholytics
   Α1-receptor blockers


































Serum creatinin (µmol/L) 88 [69 – 124] 88 [69 – 113] 87 [74 – 124]
GFR (mL/min/m²) 97.1 [46.5 – 141.5] 95.8 [74.3 – 114.7] 108.2 [46.5 – 141.5]
Ambulatory blood pressure (mm Hg)
   24 – hour systolic
   24 – hour diastolic
   Daytime systolic
   Daytime diastolic
   Nighttime systolic 
   Nighttime systolic
 
144 (± 16) 
82 (± 12) 
144 (± 14) 
85 (± 14) 
133 (± 16) 
75 (± 13)
 
142 (± 17) 
81 (± 10) 
137 (± 11) 
83 (± 9) 
132 (± 17) 
75 (± 11)
 
147 (± 16) 
83 (± 17) 
151 (± 14)* 
88 (± 16) 
136 (± 16) 
76 (± 16)
Office blood pressure (mm Hg) 
   Systolic
   Diastolic
 
158 (± 15) 
95 (± 14)
 
157 (± 13) 
96 (± 14)
 
160 (± 17) 
93 (± 15)
Heart rate (bpm) 65 (± 16) 65 (± 19) 66 (± 15)
Okada classification
Right 
   A1
   A2
   A3
   B1
   B2
Left
   A1
   A2
   A3
   B1








































Data are expressed as mean (± SD), median [range], or number (%). ACE = angiotensin converting enzyme. eGFR: estimated 
glomerular filtration rate calculated using the MDRD formula. bpm = beats per minute. 
*: p<0.05 compared to patients without renal accessory arteries
The following data have been calculated with a mixed model analysis, for we obtained 
repeated measurements in multiple patients before and after an intervention. This provided 
us with a mean and a standard error of the mean. Before RDN, RNS of the main arteries 
elicited a significant systolic BP increase of 31.5 ± 14.1 mmHg. After RDN, RNS elicited a systolic 
BP increase of 9.2 ± 6.3 mmHg (p=0.020, Figure 2). When the subgroup of 9 patients with one 
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or more accessory was studied, comparable results were observed. RNS in the main renal 
arteries elicited a systolic BP increase of 21.0 ± 3.6 mmHg prior to RDN. After RDN, RNS of the 
main renal arteries in these patients elicited a systolic BP increase of 8.2 ± 4.7 mmHg (p=0.002, 
Figure 3A). Notably, RNS in the accessory arteries resulted in a systolic BP increase of 24.5 ± 7.4 
mmHg prior to RDN. After RDN, RNS still elicited a significant BP response of 27.1 ± 7.6 mmHg 
(p=0.917, Figure 3B). When the individual data were studied only in 1 out of 6 patients with an 
accessory artery demonstrated a blunted effect of RNS in the accessory artery. 
Figure 1. Fluoroscopic image of the renal vasculature. There is a single left renal artery (*). The ostium of the main 
right renal artery is slightly lower than that of the left main artery (†). At the same height as the left main artery is 
the ostium of a smaller accessory renal artery (‡).
Figure 2. The mean SBP increase after RNS of the main renal arteries in the whole cohort before RDN is 31.5 mmHg 
with a standard error of ± 14.1 based on the mixed models analysis. The mean SBP increase after RNS of the main 
renal arteries in the whole cohort after RDN is 9.2 mmHg with a standard error of ± 6.3 mmHg (p=0.020).
64
4
RENAL SYMPATHETIC DENERVATION: RENAL NERVE STIMULATION 
 Figure 3A. In the subset of 6 patients with accessory arteries RNS in the main renal arteries elicited a systolic BP 
increase of 21.0 with a standard error of ± 3.6 mmHg based on mixed models prior to RDN. After RDN, RNS of the 
main renal arteries in these patients elicited a systolic BP increase of 8.2 with a standard error of ± 4.7 mmHg 
(p=0.002). 
Figure 3B: In the subset of 6 patients with accessory arteries RNS in the accessory renal arteries elicited a systolic 
BP increase of 24.5 with a standard error of ± 7.4 mmHg prior to RDN. After RDN, RNS of the accessory renal arteries 
in these patients elicited a systolic BP increase of 27.1 with a standard error of ± 7.6 mmHg (p=0.917).
DISCUSSION
Our study confirms that high frequency electrical stimulation of nerves in renal arteries 
(RNS), both main and accessory, elicits a substantial blood pressure increase. The amplitude 
of blood pressure increase after RNS in accessory arteries was similar to that observed in 
main renal artery trunks, suggesting that sympathetic fibers innervating accessory arteries 
may play an important role in patients with resistant hypertension. In agreement with our 
previous work,15 successful RDN of main renal arteries led to a substantial blunting of RNS-
related BP increase after electrical stimulation of denervated arteries. However, RNS of (non-
denervated) accessory arteries was associated with an unchanged blood pressure increase. 
This residual source of sympathetic activity may explain the lesser benefits of incomplete 
RDN limited to the main renal artery trunks in patients with accessory arteries.11,12 
Our findings may prove to be of major practical relevance. Indeed, the prevalence of renal 
accessory and multiple arteries varies between 15 and 30% in most populations.11,12,18 In a recent 
series of 941 hypertensive patients who underwent coronary angiography, 21% of patients had 
either aberrant or accessory renal arteries, and the mean diameter of non-principal renal 
arteries was 2.9 mm,19 which means that in a substantial proportion, RDN would not have 
been feasible. The proportion of patients with multiple renal arteries reached 34% in a Dutch 
monocentric cohort of 126 hypertensive patients referred for RDN.11 It has been hypothesized 
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that the smaller diameter of accessory renal arteries may lead to localized hypoperfusion and 
subsequent activation of the renin angiotensin system and increased blood pressure,20 thus 
explaining the higher prevalence of accessory renal arteries in severe hypertensive patients 
referred for RDN.11 
Furthermore, our results confirm that blunting of SBP increase after RNS is specific of 
denervated renal arteries, as already suggested by Chinushi et al. in their pioneering study 
of unilateral RDN in dogs.21 As such, they reinforce the hypothesis that RNS can serve as 
an intermediate end point to assess the completeness of RDN, which in its turn may be a 
predictor of blood pressure response.15, 22 In other words, a persistent increase in blood 
pressure in response to RNS after RDN might already indicate that a patient is likely to be 
a non-responder. As shown by Vink and colleagues,23 RDN does not always result in circular 
lesions completely destroying the renal nerve tissue. By applying RNS to these areas the 
remaining functional nerve tissue might be detected and ablated afterwards. From a clinical 
perspective, RNS-guided RDN may allow to optimize renal nerve ablation and to achieve 
further BP decrease after the procedure. From a more research-oriented perspective, this 
strategy may improve the completeness and reproducibility of RDN, and thus facilitate the 
identification of clinical predictors of response on this more homogeneous background. 
Notably, after the disappointing performance of RDN in Symplicity HTN-3 6 and the modest 
overall results of the technique in other recent randomised controlled trials, 24-26 identification 
of true responders to RDN is a major priority.
The fact that smaller catheters are being developed to allow access to the smaller accessory 
arteries might improve the clinical outcome for these patients. Current studies are 
investigating these catheters and results are pending. However, this will not provide the 
operators with a procedural endpoint.
Admittedly, in this study, the number of denervated patients with accessory renal arteries and 
the number of accessory renal arteries in which RNS was performed was small. We used two 
different types of stimulation catheter and a sensitivity analysis is not implemented due to the 
small number of patients. Still, the results were extremely consistent. While RNS-related SBP 
increase was maintained in accessory arteries after RDN of main renal artery trunks in 5 out of 
6 patients, only one patient showed a blunted effect in the accessory artery. Notably, the latter 
accessory renal artery was located very close to the main renal artery and both arteries might 
have shared common sympathetic nerve tissue, thus explaining this apparent discrepancy. In 
the other 5 patients we hypothesize that afferent signaling influences the central sympathetic 
tone, in line with the dog model by Chinushi and colleague, 21 since efferent effects will not 
take place this quickly and transiently. 
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Other limitations include the following: (I) RNS was performed at only 4 sites per main 
renal artery; (II) detailed renal nerve mapping in the renal arteries was not performed; (III) 
all procedures were performed under general anesthesia, which may have influenced blood 
pressure response to RNS; and (IV) our findings have not yet been correlated with long-term 
follow up to clarify clinical relevance. 
Perspectives
Our results support the concept that in patients undergoing RDN of main renal arteries, 
enhanced sympathetic tone can still be elicited by electrical stimulation of nerve tissue in 
the accessory renal arteries, with an increase in arterial blood pressure in these patients. 
These findings may at least in part explain why patients with aberrant or accessory arteries 
too small for RDN are more likely to be non-responders and our findings contribute to the 
ongoing debate about the position of renal denervation in patients with a more complex 
renal vasculature. We believe that the consensus regarding renal denervation procedures 
in patients with a more complex renal vasculature should be re-evaluated. Future studies 
with larger number of patients are warranted to assess the clinical and prognostic value of 
mapping of renal nerves with RNS in patients undergoing RDN. Finally, in order to develop 
a novel approach in which RNS-guided RDN can be performed, one has to make sure that 
the ablation catheter is positioned at the exact spot where the increase in blood pressure 
was observed. Developing a catheter that could do both mapping and ablation in one setting 




St. Jude Medical, Inc.: St. Jude Medical (Saint Paul, MN, USA) has provided funds for the 
EnligHTN system used to deliver electrical stimulation and radiofrequency energy catheter 
ablation for renal denervation. St. Jude Medical was not involved in the design of the study, 
patient recruitment, data collection, or reviewing the article
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ABSTRACT
Background: Recently we reported the use of renal nerve stimulation (RNS) during renal 
denervation (RDN) procedures. RNS induced changes in blood pressure (BP) and heart rate 
are not fully delineated yet. We hypothesized that electrical stimulation of the sympathetic 
nerve tissue in the renal artery would lead to an increase in BP and vagal stimulation would 
cause a decrease in BP. We report the different patterns of BP and heart rate responses elicited 
by RNS prior to RDN. 
Methods and results: 35 patients with drug-resistant hypertension were included. RNS was 
performed under general anesthesia at four sites in the right and left renal arteries, both 
before and immediately after RDN. RNS-induced BP and heart rate changes were monitored.
A total of 289 RNS sites in 35 patients were analyzed. An increase in systolic BP of >10 mmHg 
was regarded as a positive BP response to RNS. This pattern of response was observed in 180 
sites (62%). 86 RNS sites (30%) showed an indifferent response with BP changes £10 mmHg. At 
13 sites (4.5%) RNS elicited a decrease in BP up to -8 mmHg. However, 10 RNS sites (3.5%) showed 
a pronounced vagal response with hypotension and sinus cycle lengths ranging between 
4224-10272 milliseconds. These sites were distributed among two patients. 
Conclusion: RNS identified sympathetic and parasympathetic nerve tissue in the renal arteries. 
RNS can be potentially used to map nerve bundles and guide selective ablation of sympathetic 
nerve fibers and prevent inadvertent ablation of parasympathetic nerve tissue during RDN. 
 
Keywords: sympathetic renal denervation, vagal response, renal nerve stimulation, drug 
resistant hypertension
List of abbreviations
BP  Blood pressure
SBP  Systolic blood pressure
DBP  Diastolic blood pressure
RDN   Renal sympathetic denervation
RNS  Renal nerve stimulation
ABPM  Ambulatory blood pressure measurements
CT  Computed tomography
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INTRODUCTION
Renal sympathetic denervation (RDN) has been accepted as an experimental treatment for 
resistant hypertension because of the promising first results.1-6 Recently, we reported the use 
of renal nerve stimulation (RNS) in patients undergoing a RDN procedure.7 During RNS high 
frequency electrical stimulation is applied to identify nerve bundles in the renal artery. The 
initial increase in blood pressure (BP) in response to RNS can be used to assess the amount 
of sympathetic overdrive in these patients. This report aims at describing the patterns of BP 
response to RNS and the potential clinical implications of our findings. We believe that RNS 
can possibly be used to identify both sympathetic and parasympathetic nerve fibers. This 
identification can prevent subsequent ablation of parasympathetic fibers. It implies a major 
change in the way RDN procedures are performed. Targeting the right sites for ablation is 
an important aspect of successful RDN procedures. We hypothesized that stimulation of the 
sympathetic nerve tissue would lead to an increase in BP and stimulation of parasympathetic 
nerve fibers would elicit a decrease in BP prior to RDN. Our findings highlight once more the 
importance of RNS. 
METHODS
Patient population, inclusion and exclusion criteria 
Between May 2014 and March 2016, RDN procedures were performed with the use of RNS 
in 35 patients. These patients were referred for a RDN procedure to treat drug-resistant 
hypertension. Patients were eligible if they were on a stable antihypertensive drug regimen of 
at least 3 antihypertensive drugs (preferably with a diuretic, or less when not tolerated) for at 
least 1 month, guided by experienced physicians specialized in hypertension treatment. Office 
SBP had to be >140 or DBP >90 mmHg and 24-h ABPM SBP had to be >130 or DBP >80 mmHg 
despite stable treatment, excluding patients with white coat hypertension. Patients were 
screened for eligibility by a multi-disciplinary team, including cardiologists, internists with 
hypertension subspecialty and a radiologist. All patients were willing and able to comply with 
the protocol and had provided written informed consent. Age range for possible inclusion 
was 18-80 years and glomerular filtration rate had to be >45 mL/min/1.73m2 according to the 
MDRD formula.
Exclusion criteria were an unsuitable anatomy for RDN as assessed by CT-angiography 
(main renal artery lumen diameter ≤3 millimeter, or a total length of less than 20 millimeter 
of the main arteries), type 1 diabetes mellitus, chronic oxygen use, primary pulmonary 
hypertension, pregnancy and a mental or physical inability to participate. Patients enrolled in 
another investigational drug or device study were also excluded. Secondary hypertension was 
excluded by a rigorous protocol excluding hyperaldosteronism, pheochromocytoma, renal 
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artery stenosis (>50% stenosis in one or both arteries on CT-angiography), drug or substance 
use induced hypertension when appropriate, according to the European guidelines for the 
treatment of hypertension.8 The study was approved by the local medical ethical committee 
(ABR number 47172) and was conducted according to the declaration of Helsinki.9
Endpoints
The endpoints were acute per-procedural heart rate and BP measurements in response to RNS. 
Procedure
All patients were under general anaesthesia induced by Propofol, supervised by a cardiac 
anaesthesiologist. Throughout the RDN procedure, no changes were made in use of vasoactive 
medication and no inotropic medication was necessary. The procedure was performed by 
experienced interventional cardiac electrophysiologists. Two sheaths were placed in the right 
femoral artery; one for continuous BP recording and one for RNS/RDN catheter access. 5000 
IU of heparin was administered during the procedure. 
In addition, in patients not using acetylsalicylic acid, 500 mg of acetylsalicylic acid IV was 
administered. Aorto-renal angiography was performed using a pigtail catheter. 
Initially, a conventional quadripolar catheter with a tip electrode of 2 mm, 3 proximal 
electrodes of 1 mm and interelectrode spacing of 5 mm (EP-XT, C.R. Bard, Inc., Murray Hill, 
NJ, USA) was introduced in the renal artery, under fluoroscopic guidance. Bipolar stimulation 
was performed between the distal electrode pair of the catheter. This catheter was used only 
when performing RDN with the single-electrode ablation catheter (Symplicity Flex Renal 
Denervation Catheter, Medtronic, Minneapolis, MN, USA). In patients who were ablated with 
the multi-electrode basket ablation catheter (EnligHTN, St Jude Medical, Saint Paul, MN, USA), 
bipolar stimulation was performed by delivering electrical pulses through the electrodes of 
this multi-electrode basket catheter, with bipolar stimulation from pole 1-2 and 3-4 proximally 
and distally in the renal artery. The first renal artery to undergo RNS was alternated between left 
and right among consecutive patients. RNS was performed at multiple sites with a minimum 
of 4 sites in each artery, ensuring that different quadrants of the arterial circumference were 
stimulated in proximal and distal areas of the renal artery, in which ablations are usually 
performed. Pacing frequency was set at 20 Hz, pacing output at 20 mA with a pulse duration of 
2 ms, based on earlier research.7,10-13 Stimulation duration was 60 sec, or shorter when systolic 
BP increased beyond 180 mmHg. We chose this as a cut-off point as we experienced additional 
BP rises up to >200 mmHg after stopping stimulation in previous research. We waited for the 
BP to return to baseline values before proceeding to a next stimulation site. After RNS in both 
arteries (total of at least 8 stimulation sites) a standard RDN procedure was performed. The 
single-electrode Medtronic renal ablation catheter was used in 14 patients and the St. Jude 
multi-electrode EnligHTN catheter in 20 patients. In 1 patient, a combination of both single 
74
5
RENAL SYMPATHETIC DENERVATION: RENAL NERVE STIMULATION 
electrode and multi-electrode RDN catheters was used. In this latter patient, the left renal 
artery was denervated with the multi-electrode basket catheter. We switched to the flexible 
single electrode catheter due to anatomical variation prohibiting the introduction of the 
multi-electrode basket catheter in the right renal artery. 
The use of the single electrode catheter (Symplicity, Medtronic) has been described 
previously.7 The multi-electrode RDN catheter contains 4 electrodes separated from each 
other in a basket configuration. The protocol has been described previously as well.14,15 In each 
renal artery, between 8 and 24 ablation points were delivered by subsequent sets of RF energy 
applications. During RF energy application, tip temperature and impedance were monitored 
to ensure proper ablation. 
Patients were followed and monitored as an outpatient by a vascular internist. In all 
patients a validated 24h ABPM with 30 min. BP measuring intervals was obtained (Spacelabs, 
Snoqualmie, WA) at 3, 6 and 12 months after the procedure to assess the effect of RDN. 
Office BP measurements were executed by repeated automated oscillometry measurements 
(intrinsically blinded) or by sphygmomanometry by technicians not involved in the analysis 
of the study (regarded blinded). 
RESULTS
The baseline characteristics of the 35 patients are summarized in Table 1. RNS was applied 
prior to RDN at 289 sites in 35 patients (left and right renal arteries combined). We observed 
three patterns of response to RNS: 
1. Sympathetic response with a SBP increase of >10 mmHg during RNS. 
•	 Sympathetic response is defined as an increase in systolic BP of >10 mmHg. 
The increase in BP started half way RNS and continued slightly after RNS was 
discontinued. We observed a RNS-induced decrease in cycle length from 1210 ± 201 
ms to 1170 ± 203 ms before RDN (P = 0.028) without a change of the depth of general 
anaesthesia determined by bispectral index (BIS).
2. Indifferent response to RNS with no or negligible change in BP, i.e. BP increase ≤10mmHg
•	 Indifferent response is defined as an increase in systolic BP of ≤10 mmHg. We 
observed no increase in heart rate, or in change of the depth of general anaesthesia 
determined by BIS.
3. Vagal response to RNS with bronchospasm and BP drop due to bradycardia (cycle length 
increasing up to 10272 ms).
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Follow up at 
3 or 6 months
Age (years) 63 (± 8)
Sex 
   Males   20 (57%)
Body-mass index (kg/m2) 29.9 (± 4.0)
Current smokers 2 (5.7%)
Medical history 
   Hypercholesterolemia 
   Type 2 diabetes mellitus 
   Coronary artery disease





Number of antihypertensive medications  4 [2 – 6] 4 [1-6]
Class of antihypertensive medication
   Diuretic
   Aldosterone receptor blocker
   Beta-blocker
   Calcium channel blocker
   ACE- inhibitor
   Angiotensin receptor blocker
   Aliskiren
   Centrally acting α2-sympatholytics
   Α1-receptor blockers






















Serum creatinin (µmol/L) 76 [51 – 124]
GFR (mL/min/m²) 76.6 [39.8 – 113.0]
Ambulatory blood pressure (mm Hg)
   24 – hour systolic
   24 – hour diastolic
   Daytime systolic
   Daytime diastolic
   Nighttime systolic 
   Nighttime systolic
 
144 (± 14) 
81 (± 12) 
147 (± 13) 
83 (± 12) 
133 (± 13) 
73 (± 12)
135 (± 13), P = 0.004
77 (± 11),  P = 0.070
138 (± 12), P = 0.008
79 (± 11),  P = 0.080
128 (± 13), P = 0.074
69 (± 10),  P = 0.070
Heart rate (bpm) 69 (± 14)
Office blood pressure (mm Hg) 
   Systolic
   Diastolic
 
161 (± 19) 
92 (± 14)
144 (± 21), P = 0.002
82 (± 13),  P = 0.023
Okada classification
Right 
   A1
   A2
   A3
   B1
   B2
Left
   A1
   A2
   A3
   B1














Data are expressed as mean (± SD), median [range], or number (%). ACE = angiotensin converting enzyme. bpm = beats per minute. 
eGFR: estimated glomerular filtration rate calculated using the MDRD formula.
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Either a site would demonstrate an increase in BP following RNS, or it would demonstrate an 
indifferent reaction without a change in BP. Notably sinus cycle length decreased from 1210 ± 
201 ms to 1170 ± 203 ms (P = 0.028) before RDN. After RDN sinus cycle length did not decrease 
significantly (991 ± 590 ms to 986 ± 588 ms, P = 0.583). When an increase in BP was observed 
there appeared to be two distinct patterns. Either there was an immediate increase in BP or 
the increase in BP started slightly later, but continued to increase even though RNS had been 
terminated. It was this latter observation that made us discontinue RNS when a systolic BP of 
180 mmHg was reached. 
An increase in systolic BP of >10 mmHg was regarded a positive response to RNS. This pattern 
of response was seen in 180 sites (62%). 86 RNS sites (30%) showed an indifferent response with 
BP changes £10 mmHg. At 23 sites (8.0%), RNS elicited a decrease in BP. At 13 of these sites BP 
drops ranged from -1 to -8 mmHg. 10 of these 23 RNS sites showed a pronounced vagal response 
with sinus arrests ranging between 4224-10272 ms. These sites were distributed among two 
patients. Both patients demonstrated a mixed response to RNS, ranging from sites that 
elicited a large BP increase to the mentioned vagal response. We observed the vagal response 
both distally and proximally in the renal arteries. These results have been summarized in a 
flowchart (Figure 1).
Figure 1. This figure displays the flowchart that summarizes the results that we have obtained in 35 patients. A 
total number of 289 have been analyzed. 180 sites demonstrated a BP increase. 86 sites demonstrated an indifferent 
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Details of a representative example of a pronounced increase in BP are illustrated in Figure 2. 
This figure displays a pronounced effect of BP increase in response to RNS. Panel A demonstrates 
normal sinus rhythm with a cycle length of 1152 ms and a BP of 100/46 mmHg. RNS is applied 
(RNS artefacts on the ECG). Panel B shows termination of RNS and a new situation in which 
the BP is increased to 149/59 mmHg and no effect on sinus cycle length (1184 ms). An example 
of an indifferent response is shown in Figure 3. This figure displays an indifferent effect of BP 
increase in response to RNS. Panel A demonstrates normal sinus rhythm with a cycle length 
of 1216 ms and a BP of 111/49 mmHg. RNS is applied (RNS artefacts on the ECG). Panel B shows 
termination of RNS and an unchanged situation in which the BP is 109/49 mmHg and no 
effect on sinus cycle length (1312 ms). 
Figure 2. This figure displays a pronounced effect of BP increase in response to RNS. Panel A demonstrates normal 
sinus rhythm with a cycle length of 1152 ms and a BP of 100/46 mmHg. RNS is applied (RNS artefacts on the ECG). 
Panel B shows termination of RNS and a new situation in which the BP is increased to 149/59 mmHg and no effect 
on sinus cycle length (1184 ms). 
Figure 3. This figure displays an indifferent effect of BP increase in response to RNS. Panel A demonstrates normal 
sinus rhythm with a cycle length of 1216 ms and a BP of 111/49 mmHg. RNS is applied (RNS artefacts on the ECG). 
Panel B shows termination of RNS and an unchanged situation in which the BP is 109/49 mmHg and no effect on 
sinus cycle length (1312 ms). 
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An illustrative example of the vagal response we have observed is depicted in Figure 4. This 
figure displays a vagal effect on BP in response to RNS. Panel A demonstrates a RNS-induced 
sinus cycle length prolongation of 10272 ms. RNS was terminated immediately and sinus 
rhythm was restored. The pronounced drop in BP from 110/50 mmHg to 70/35 mmHg was 
noted. Panel B demonstrates response to RNS at a different site in the same patient. It resulted 
in extreme bradycardia (maximum cycle length 9376 ms) and subsequent drop in BP to 80/40 
mmHg. After termination of RNS, BP increased and regular sinus rhythm was restored. All 
RNS effects on sinus rate and BP were reversible. 
Figure 4. This figure displays a vagal effect on BP in response to RNS. Panel A demonstrates a marked RNS-induced 
RR interval increase to 10272 ms. RNS was terminated immediately and sinus rhythm was restored. The pronounced 
drop in BP from 110/50 mmHg to 70/35 mmHg can be noted. Panel B demonstrates response to RNS at a different site 
in the same patient. It resulted in extreme bradycardia (maximum RR interval 9376 ms) and subsequent drop in BP 
to 80/40 mmHg. After termination of RNS regular sinus rhythm was restored.
As a group, BP of our patients responded significantly at 3 to 6 months of follow up. Mean 
systolic BP declined from 144 (± 14) to 135 (± 13), P = 0.004. Daytime systolic BP declined from 
147 (± 13) to 138 (± 12), P = 0.008. However night-time systolic BP declined from 133 (± 13) to 128 (± 
13), which did not reach statistical significance, P = 0.074. Diastolic BP did not reach statistical 
significance, but declined numerically. See Table 1. 
Detailed description of the 2 patients that demonstrated a vagal response pattern are 
presented here. The first patient was a 66 year old woman referred by her general practitioner 
to an internist with hypertension subspecialty due to difficulty with establishing an effective 
antihypertensive drug regimen to control hypertension. Average office BP measurements 
was 165/60 mmHg when she was initially screened. The subsequent 24h ABPM daytime BP 
was 132/55 mmHg whilst being put on four different types of antihypertensive medication 
(diuretic, β-blocker and the combination of an ACE-inhibitor and AT1-antagonist, which was 
switched to a calcium channel antagonist during the screening). Because she did not tolerate 
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her medication and she was found to have micro albuminuria she was regarded a suitable 
patient for RDN. Screening for secondary hypertension did not show any abnormalities. 
This patient did not experience (symptoms of ) orthostatic hypotension before RDN. She 
did not have other traditional risk factors for cardiovascular disease (i.e. smoking, diabetes, 
hypercholesterolemia, vascular disease or obesity). This patient did not demonstrate a 
beneficial effect of RDN during follow up; 24h ABPM daytime BP was 141/58 mmHg. 
The second patient with a pronounced vagal response to RNS was a 70 year old woman referred 
to the internist with hypertension subspecialty by the cardiology department to screen her 
for secondary hypertension and eligibility for RDN. Besides hypertension she suffered from 
type 2 diabetes and hypercholesterolemia. Average office BP measurements were 155/80 mmHg 
when she was initially screened. The 24h ABPM daytime BP was 146/79 mmHg whilst being 
put on five different types of antihypertensive medication (combination of two diuretics, 
β-blocker, an ACE-inhibitor and an α1-blocker). Because she was still hypertensive despite 
extensive medical therapy she was referred for RDN as well. During follow up this patient 
demonstrated a slight beneficial effect of RDN; 24h ABPM daytime BP was 136/72 mmHg whilst 
being on the same drug regimen. 
DISCUSSION 
Electrical stimulation in renal arteries may identify different patterns of response to RNS. 
Even though we cannot proof histologically that parasympathetic fibres are responsible for 
the observed vagal effect, it is very likely that activation of the aortico-renal parasympathetic 
ganglia elicited the observed pronounced vagal response. Potentially, RNS technique can 
be used to map nerve bundles in renal arteries and guide selective ablation of sympathetic 
nerve tissue. In addition, RNS may probably prevent inadvertent ablation of parasympathetic 
nerve tissue during RDN. Taking into account the number of non-responders to RDN, this is 
an interesting possibility that warrants further analysis16.
We previously demonstrated that RNS is feasible in patients with drug-resistant hypertension 
undergoing RDN.7 Furthermore, we showed that an increase in BP can still be elicited in 
accessory arteries when denervation of the main renal arteries was performed.14 Finally, we 
demonstrated in a small cohort that RNS predicts 24h ABPM data during follow up after a RDN 
procedure.15 During our data collection we encountered an unexpected, but very interesting 
finding: the occurrence of bradycardia/sinus arrest and hypotension during RNS. The rationale 
of RNS comprehends the activation of the sympathetic nerve tissue surrounding the renal 
arteries and its afferent coupling with the central sympathetic nervous system.10 Also renal 
nerves play a key role in the communications between the kidneys and the central nervous 
system to maintain homeostasis. An increased sympathetic nerve activity to the kidney and 
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the renal afferent nerve activity to the CNS may contribute to the outcome of diseases, such as 
hypertension17. Through this mechanism RNS elicits the observed BP increase and sinus cycle 
length decrease. In two patients we observed the opposite response. They developed sinus 
bradycardia/sinus arrest with subsequent hypotension and bronchospasm at the same time. 
Since data on RNS in human hypertensive patients are scarce and this observation has only 
been described in one case,18 we believe this information is essential to report. This finding 
underlines the rationale and importance of RNS in RDN procedures both before and after 
RDN. An extensive ablation at the sites that show a vagal response will presumably not lower 
BP during follow up. The ablation might even cause an increase in BP after RDN, due to 
ablation of parasympathetic nerve fibres, potentially enhancing sympathetic overdrive. We 
did not perform ablation at these specific sites to avoid these consequences, preventing us to 
compare the effect of RNS before versus after RDN at these specific sites. We observed vagal 
responses in 2 out of 35 patients (5.7% of the cases). This may even be one of the contributing 
factors that help to explain the variable drop in arterial BP after RDN.19 
We analysed the two patients that demonstrated a vagal response pattern in more detail to 
determine if we could or should have foreseen their profound vagal response to RNS. After 
analysing their reported patient characteristics we concluded that both patients are no 
exception to the population referred for RDN. 
Ablation of the parasympathetic fibres from the aorticorenal ganglia is an undesirable but 
possible result of a conventional ‘blind’ RDN procedure.20 Since the innervation of the renal 
artery is variable in patients21 there is no empiric possibility of preventing the ablation of 
vagal fibres from these ganglia, unless ablation points are placed in distal parts in the renal 
arteries.22 We believe that a vagal response was found only in those patients in whom the 
parasympathetic nerve fibres were located in close proximity to the vessel wall and were 
identified by RNS. The point of RDN is not to target these fibres, even though not much is 
known about their ablation. We are relieved to not demonstrate the effect more often, and 
assume that the majority of the patients do not have parasympathetic fibres in very close 
proximity to the renal artery ostia. A limitation is that our findings are based on a clinical 
response to RNS, but we lack the anatomical proof of the location of the parasympathetic 
fibres in these two patients. The fact that this phenomenon has not been described before is 
related to the very limited use of RNS during RDN procedures in other centres. The use of RNS 
enables detection of vagal responses, preventing inadvertent ablation of parasympathetic 
nerve tissue. RF ablation of sites with indifferent response to RNS, i.e. sites that do not 
demonstrate an enhanced BP response to RNS seems ineffective and undesirable. We 
advocate the use of RNS to identify sympathetic nerve tissue for selective ablation instead of 
conventional ‘blind’ placement of ablation points in the renal arteries. 
Some may argue that the vagal response is due to activation of pain fibres. We do not believe 
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this assumption because of the stable bispectral index (BIS), measured to monitor the depth 
of anaesthesia. It remained stable in all patients, and in particular during the episodes of 
vagal response to RNS, ensuring a stable depth of anaesthesia. In addition, we administered 
intravenous opioids to prevent pain reaction to heating of the tissue by ablation. Of note, 
ablation of pain fibres innervating the kidneys is of no use in the treatment of drug resistant 
hypertension. RNS could possibly be used to avoid that, if this would be the case. 
We believe that use of RNS during RDN has a strong rationale and that patient selection and 
conventional ‘blind’ ablation technique are the main reasons why previous RDN studies 
reported such divergent results. In our previous work we demonstrated residual physiologically 
active sympathetic nerve tissue in accessory arteries.14 These accessory arteries may contribute 
to enhanced sympathetic drive and increased BP after ablation of the main renal arteries. We 
demonstrated that the initial increase in BP in response to RNS might serve as an indicator of 
sympathetic overdrive. The difference between the response before RDN and after RDN was 
significantly correlated with the decrease in 24h BP. The extent of this difference might serve 
as an endpoint to assess completeness of RDN. During these procedures we discovered the 
important possibility of eliciting a response to RNS which consists of bronchospasm, asystole 
and subsequent hypotension which appeared to be completely reversible. We believe that 
this response is not caused by stimulating the sympathetic nerve tissue through the renal 
arteries, but the stimulation of the parasympathetic fibres in the aorticorenal ganglia which 
are located ostially adjacent to the renal arteries18.
Conclusion
RNS enables functional identification and localization of both sympathetic and 
parasympathetic nerve tissue and use of the RNS technique may guide selective ablation of 
the sympathetic nerve fibres adjacent to the renal artery and improve the efficacy of RDN. In 
addition, RNS may help in preventing inadvertent ablation of parasympathetic nerve tissue 
in close proximity to the renal arteries. 
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CHAPTER VI
Renal Nerve Stimulation as 
procedural end point for 
Renal Nerve Denervation
Review
A.F. Hoogerwaard, MD, M.R de Jong, A. Elvan MD PhD.1 
1 Department of Cardiology, Isala Hospital, Zwolle, The Netherlands 
Curr Hypertens Rep. 2018 Mar;19;20(3):24
Purpose of review: Renal nerve denervation (RDN) as treatment option for hypertension has 
a strong rationale, however variable effect on blood pressure (BP) have been reported ranging 
between non response to marked reductions in BP. The absence of a procedural end point 
for RDN is a possible explanation for the variable response, it is suggested that renal nerve 
stimulation (RNS) can be used to solve this problem. This review aims to summarize on the 
clinical and non-clinical data available of the effects of renal nerve stimulation (RNS).
Recent findings: Animal studies have shown that high frequency electrical stimulation of 
the renal arteries leads to increase in BP and increased norepinephrine spillover as a marker 
of increased sympathetic activity and that these effects of stimulation are blunted after RDN. 
In a human feasibility study using RNS both before and after RDN same responses on blood 
pressure have been showed. On top of that in a small study RNS induced changes in blood 
pressures appeared to be correlated with 24-hour BP response after RDN. 
Key words: renal nerve stimulation, renal nerve denervation, drug-resistant hypertension
Abbreviations
ABPM  Ambulatory blood pressure measurements
BP  Blood pressure
DBP  Diastolic blood pressure
ENS  Electrical nerve stimulation
HR  Heart rate
RDN  Renal nerve denervation
RNS  Renal nerve stimulation
SBP  Systolic blood pressure
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INTRODUCTION
Dysregulation of the autonomic nervous system, particularly imbalance between sympathetic 
and vagal tone, has been implicated in the development and maintenance of hypertension.1,2 
In this context renal nerve denervation (RDN) has been developed as a potential treatment 
for resistant hypertension;3–5 its rationale originates in denervating the renal sympathetic 
efferent and afferent coupling with the central autonomic nervous system. In 2009, the first 
patient with treatment resistant hypertension who underwent RDN was reported.6 After the 
RDN procedure the patient had substantially reduced blood pressure (BP) and whole-body 
norepinephrine concentrations as a parameter of decreased sympathetic outflow. Thereafter, 
Krum and colleagues showed in a proof of concept study in a cohort of 45 patients with 
resistant hypertension the safety and effectivity of RDN with a significant decline in office 
BP of 32/12 mmHg at 12 months follow-up.7 This study was followed by the Symplicity HTN-
2 trial in which the investigators established in 106 patients who were randomly allocated 
to RDN or control that office BP significantly decreased by 32±23/12±11 mmHg in the RDN 
group (p<0.0001), whereas the BP in the control group remained unchanged compared to 
baseline at 6 months follow-up.8 After the HTN-2 trial the ESC Guidelines stated that RDN 
may be considered as a possible treatment option for patients with resistant hypertension.9 
After these promising results of RDN on lowering BP the last step before definite proof 
of the efficacy of RDN was a blinded, randomised, sham-controled controlled trial. The 
Symplicity HTN-3 trial was subsequently started and included 535 patients assigned in a 2:1 
ratio to RDN or a sham procedure. The trial confirmed again the safety of the RDN procedure; 
however it failed to demonstrate a benefit on RDN on reduction in 24-h ambulatory blood 
pressure measurements (ABPM) during follow-up.4 This discrepancy between the results 
of the first blinded, sham-controlled HTN-3 trial and previous studies raised concern and 
a number of possible explanations for the results of the HTN-3 trial were suggested. Part of 
the explanations were procedural related since there is no procedural end point for the RDN 
procedure; probably effective denervation had not occurred in all patients randomised to 
the RDN group due to inadequate radio frequent lesions,10 wrong locations were denervated 
due to anatomical variations of perivascular nerves and ganglia 11 or due to the presence of 
aberrant renal arteries there was still residual autonomic nerve activity post RDN.12 The other 
part of the explanations for the results of the Symplicity HTN-3 trial were patient or physician 
related.13 Subsequently many papers have been published addressing these issues. However, 
very recently the results from another single-blind, randomised, sham-controlled trial has 
been published and showing again proof of principle for the BP lowering efficacy of RDN. The 
RDN group (n=38) showed a decrease of 5.5[-9.1, -2.0]/4.8 [-7.0, -2.6] mmHg on 24-h ABPM at 3 
months follow-up, whereas the BP in the control group (n=42) remained unchanged.5 
Summarizing, overall the rationale of RDN as possible new treatment remains very attractive 
and there is evidence supporting this rationale. However, results on lowering blood pressure 
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have been variable with a wide spectrum ranging between non response to a marked reduction 
for different reasons. These reasons have highlighted the crucial need for a functional test to 
define the optimal denervation target site and a clear procedural end point for RDN. In order 
to create a procedural end point for the RDN procedure, renal nerve stimulation (RNS) has 
been developed and studied and this review will focus on the data available to use RNS during 
the RDN procedure. 
Renal Nerve Stimulation in animal models
Chinushi et al. reported in dogs about the use of electrical nerve stimulation (ENS) of the renal 
arteries aiming to study the role of the autonomic nerves and radio frequent (RF) ablation of 
the renal artery in the regulation of BP.14 They electrically stimulated the proximal portion of 
the renal arterial nerves before and after RF catheter ablation. Dogs were anesthetized with 
tiopenthal and to minimize pain sensitization during electrical stimulation pentazocine 
intravenous (i.v.) was administered. Before RDN, they showed a significant increase in BP 
(from 146±17/89±17 mmHg to 170±23/103±19 mmHg, p<0.001) and HR (from 119±9 bpm to 
131±7 bpm, p<0.001). After RDN, no significant changes in either BP (150±20/90±16 mmHg 
to 152±20/92±17 mmHg) or heart rate (HR) (from 124±14 bpm to 124±14 bpm) were observed. 
Besides these ENS-induced BP effects, the authors showed that the serum epinephrine and 
norepinephrine concentrations significantly increased due to ENS before RDN, whereas after 
RDN the concentrations only minimally increased. This finding suggests that the ENS-induced 
increase in BP and HR were attributed to an increase in systemic sympathetic nervous activity. 
Importantly, no angiographic damages to the renal arteries were observed after ENS. In a 
following study Chinushi et al. aimed to demonstrate that these BP responses to ENS could 
be used an indicator of successful modulation of the renal autonomic nerve function. Again 
in a canine model, they showed with histological proof that the suppressive effects of ENS-
induced increase in BP by RDN may be related to the severity of tissue injury.15 So, functional 
RDN seems performable with the guidance of ENS. In the corresponding letter to this article 
authors highlight the standardization of stimulation protocols and systematic evaluation 
of anaesthetic use considering disappointing results of ENS in their porcine model.16 Sun 
et al.17 showed also in dogs comparable results as Chinusi et al.14, i.e. a significant increase in 
systolic BP after applying ENS to the renal arteries. However, HR did not significantly change 
in their model and they hypothesize that this is due to a result of baroreceptor independent 
sympathetic activation.18 These results on BP are also confirmed by Lu et al. who assessed 
again in a canine model the efficacy of ENS-guided RDN and showed that ENS-guided targeted 
ablation can achieve apparent BP reduction and central sympathetic inhibition measured by 
plasma norepinephrine changes.19 
Summarizing, animal models, mainly using dogs, have given supportive evidence that ENS 
can be used to localize the sympathetic nerves before RDN and ENS-induced BP effects are 
blunted after RDN. Of note, the autonomic anatomy of the renal nerves shows important 
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differences between dog and man.20 
Renal Stimulation Protocol
In 2015 for the first time a clinical study using high-frequency RNS before and after a RDN 
procedure in patients with resisted hypertension was reported.21 The study aimed to design 
a RNS protocol and determine the effects of RNS in the renal arteries on BP and HR before 
and after RDN. The latter will be discussed in the next section, in this paragraph we will focus 
on the pacing and output settings during RNS. Pacing frequency was set at 20 Hz, conform 
previous studies from Chinushi et al.14. In 4 patients pacing output settings were gradually 
increased (5, 10, 15, 20 mA) to determine the pacing output threshold. Only with a pacing 
output setting exceeding 10 mA a BP response was observed and pacing output was set at twice 
the threshold. In the first four patients RNS duration was set at three minutes; however BP 
response was observed already after 30 seconds. Therefore RNS duration was set at twice the 
threshold, at 1 minute. In three patients the repeatability of RNS was tested with mentioned 
settings and no significant differences were found between the two measurements.
Renal Stimulation in human
In the mentioned feasibility study, RNS has been used both before and after RDN in eight 
patients.21 Patients in this study had a mean age of 66 ± 5.6 years, baseline ABPM of 153±13/89±4 
mmHg and were using an average of 4 [3-6] antihypertensive drugs. In accordance with the 
mentioned animal models,14,15,17,19 RNS-induced a systolic BP response of + 43 ±15 mmHg before 
RDN compared with +9±10.5 mmHg after RDN, p=0.0002. Also sinus cycle length significantly 
shortened before RDN due to RNS (1286.9±173 ms to 1069±274 ms, p < 0.001). And after RDN 
sinus cycle length shortening was significantly reduced (+211 ms versus +45 ms, p=0.015). 
This study showed for the first time in man that RNS resulted in a temporarily increase in 
BP, and this effect is blunted after RDN. In order to implement RNS as a reliably predictable 
procedural end point for the RDN procedure it should also be correlated to BP responses at 
follow-up. So, De Jong et al.22 investigated whether 24-h ABPM changes after RDN correlated 
with acute per-procedural RNS-induced BP responses. In the analysis were fourteen patients 
included with a mean age of 66 [39-76] years, half of their population was male and the 
average 24-h ABPM was 153±11/88±8 mmHg at baseline. In agreement with the results from 
the feasibility study 21 RNS induced a systolic BP increase (50±27 mmHg) before RDN, and this 
effect was again blunted after RDN (13±16 mmHg) (p<0.001). At 3 to 6 months follow-up ABPM 
was significantly decreased to 137±10/80±9 mmHg, p = 0.003/0.018. With a Pearson correlation 
authors show subsequently that the RNS-induced SBP rise before RDN at the site of maximum 
response is significantly correlated with changes in systolic ABPM at a median of 4.5 months 
follow-up (R=0.610, p=0,020). The correlation further increased after subtracting the RNS-
induced BP rise measured immediately after RDN, (delta BP at site of maximum response 
defined as RNS-induced BP before RDN minus the RNS-induced BP after RDN) showing a 
significant correlation with 24-h BP response at follow-up (R=0.769, p=0.001). These results 
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show the potential of using RNS as functional test to evaluate the efficacy and predict the 
clinical outcome of the RDN procedure. The same research group showed that RNS of non-
denervated accessory arteries was associated with an unchanged BP increase both before 
and after RDN.23 This residual source of sympathetic activity may partly explain why some 
patients are non-responders to RDN due to anatomical variations. But these results give also 
supportive evidence using RNS as a procedural end point; because of a persistent increase in 
BP in response to RNS after RDN might indicate that a patient is likely to be a non-responder 
due to an incomplete RDN. 
Pathophysiological mechanism of RNS
The exact pathophysiological mechanism of as well RDN as RNS is yet not completely 
understood. As established in the animal studies RNS leads to increase in serum epinephrine 
and norepinephrine concentrations as markers of an increased sympathetic activity.1,14 
Nammas et al. 24 described the cardio/renal sympathetic interaction, showing afferent renal 
sympathetic nerve signaling regulating central sympathetic outflow. We believe described 
RNS-induced changes in BP are due to increasing the central sympathetic tone through an 
afferent mechanism. The sympatho-excitatory renal afferent reflex is a likely cause of the 
rise in blood pressure induced by electrical stimulation, because the rise in blood pressure 
15-30 seconds after starting electrical stimulation which was consistent with an increase in 
sympathetic nervous activity through stellate ganglion stimulation in canine studies as 
reported previously.25 Other experimental data indicate also that the afferent nerves play 
an important role in the RNS-induced BP response.26,27 Plasma renin activity and creatinin 
clearance are not affected by RDN, suggesting that efferent renal efferent nerve activity does 
not play an important role. On top of that efferent nerve fibers would take more time to 
increase BP, so therefore likely not to explain the transient BP increase due to RNS.28 Since BP 
was measured with a femoral artery line during the RNS procedure 21,22 renal vasoconstriction 
cannot explain either the temporarily RNS-induced BP increase. However, further research 
regarding the pathophysiological mechanisms is needed.
Clinical applications
Up to now, there is evidence from small studies that RNS can be used to identify sympathetic 
nerve fibers in patients with treatment resistant hypertension undergoing RDN and that 
is predicts BP response at follow-up. In the future RNS-guided RDN may possibly allow 
optimizing RDN and achieving further BP decrease after the RDN procedure. 
Conclusions
RNS has proven in to induce increases in BP and HR before RDN and these effects are blunted 
after RDN. Moreover there is also evidence that the RNS-induced BP increases predict 
outcome on 24-h ABPM at follow-up. However, studies are small and limited. The exact 
pathophysiological mechanism of RNS increasing BP is not well studied. 
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CHAPTER VII
Treatment of atrial fibrillation in 
patients with enhanced  sympathetic 
tone by pulmonary vein isolation 
or pulmonary vein isolation 
and renal artery denervation: 
clinical background and study design
The ASAF trial: ablation of sympathetic atrial fibrillation
ABSTRACT
Background: Hypertension is an important, modifiable risk factor for the development of 
atrial fibrillation (AF). Even after pulmonary vein isolation (PVI), 20-40% experience recurrent 
AF. Animal studies have shown that renal denervation (RDN) reduces AF inducibility. One 
clinical study with important limitations suggested that RDN additional to PVI could reduce 
recurrent AF. 
Objective: The goal of this multicenter randomized controlled study is to investigate whether 
RDN added to PVI reduces AF recurrence. 
Methods: The main end point is the time until first AF recurrence according to EHRA 
guidelines after a blanking period of 3 months. Assuming a 12 month accrual period and 12 
months of follow-up, a power of 0.80, a 2-sided alpha of 0.05 and an expected drop-out of 10% 
per group, 69 patients per group are required. We plan to randomize a total of 138 hypertensive 
patients with AF and signs of sympathetic overdrive in a 1:1 fashion. Patients should use at least 
2 antihypertensive drugs. Sympathetic overdrive includes: obesity, exercise-induced excessive 
blood pressure (BP) increase, significant white coat hypertension, hospital admission or fever 
induced AF, tachycardia induced AF and diabetes mellitus. The interventional group will 
undergo PVI + RDN and the control group will undergo PVI. 
Results: Patients will have follow-up for 1 year, and continuous loop monitoring is advocated. 
Conclusion: This randomized, controlled study will elucidate if RDN on top of PVI reduces 
AF recurrence.
Keywords: RDN, PVI, AF, hypertension, sympathetic overdrive
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INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia and its prevalence rises exponentially 
after the age of 60 years. It is expected that the prevalence of AF will increase in the ageing 
population of Europe in the upcoming years. Besides its disabling symptoms, AF is associated 
with serious morbidity (e.g. thromboembolism, CVA, heart failure) and increased mortality.1 
Results of medical therapy to prevent AF are very modest, and reported as 30% success in 
achieving long term sinus rhythm. Catheter ablation of AF (i.e. pulmonary vein isolation, 
PVI) is significantly more successful in obtaining and maintaining sinus rhythm with a 
success rate of 60-80% after one or more interventions. The rationale of PVI for AF lies in the 
fact that arrhythmogenic foci arising from the pulmonary veins induce fibrillatory electrical 
activity in the left atrium, hereby initiating and perpetuating AF. It is hypothesized that this 
mechanism is most important in patients with paroxysmal AF. If AF recurs more than once 
but terminates spontaneously within seven days, the term paroxysmal AF is used. This is also 
used when the episode is less than 48 hours in duration and is terminated with electrical or 
pharmacological cardioversion. Persistent AF is defined as recurrent AF that is sustained for 
more than seven days. A patient who is electrically or pharmacologically cardioverted after 
more than two days is also diagnosed with persistent AF. The AF recurrence rates are even 
higher in patients with persistent AF (40-50%). Experimental and clinical research have shown 
that the autonomic nervous system has an important role in the induction and persistence 
of AF, and on the histopathological and electrical substrate in the atria (fibrosis, functional 
conduction blocks).2,3 This has drawn the attention of cardiac electrophysiologists to the 
treatment of modifiable factors in order to prevent AF episodes.4 Is has been reported that 
patients with sympathetically induced (supra)ventricular arrhythmias in the setting of 
resistant hypertension remained free of arrhythmias after renal artery denervation (RDN).2,5-7 
It is hypothesized that by applying ablational therapy in the renal arteries, the connection 
of the sympathetic nervous system within the renal arterioles is at least partially severed.8 
See Figure 1 for a summary of the mechanisms between the central nervous system, the 
kidneys and the heart that initiate arrhythmia. By applying this new interventional therapy 
in patients with therapy resistant hypertension, it was demonstrated in several reports that 
the sympathetic overdrive inducing hypertension was prevented, and significant reductions 
in blood pressure were achieved.6,8-13 Furthermore a beneficial effect on cardiac (diastolic) 
function was shown.14 Pre-clinical trials carried out by Liang et al demonstrate that RDN 
prevents AF inducibility in a dog model.15 Similar results have been found in a rabbit heart 
failure model.16 Furthermore, in a small clinical study, 27 patients with AF were randomised 
to PVI or PVI + RDN. Patients who underwent PVI + RDN had significantly less episodes of AF 
than those undergoing PVI alone.17 This report however involved a very limited number of 
patients, had important study limitations rendering its results less reliable, and consisted of 
a very selected group. Loop recorder data of these patients demonstrated a lower AF burden 
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in patients that underwent RDN.18 We hypothesize that patients who have paroxysmal or 
persistent AF, with hypertension (systolic >140 mmHg or >130/80 mmHg in diabetics and 
patients with chronic renal disease according to the ESC guideline on arterial hypertension19) 
and signs of sympathetic overdrive, will benefit from RDN on top of the standard ablative 
therapy (PVI). Therefore, we have initiated a randomised controlled trial that will assess 
the effects of PVI and RDN+PVI on the success of preventing AF recurrence. Furthermore 
we will assess the effect of these therapies on several aspects of the cardiovascular system 
and the autonomic nervous system. The study is listed at clinicaltrials.gov (NCT02115100). 
Figure 1. Mechanism of arrhythmia triggering through the reno-cardiac axis (re-use courtesy of Heart Rhythm).
METHODS
Primary aim
To investigate if renal artery denervation in combination with pulmonary vein isolation, 
prevents AF recurrence significantly better in patients with out of range hypertension and 
signs of sympathetic overdrive.
Secondary aim(s):
Investigate the effects of renal artery denervation on the sympathetic innervation of the 
heart and the general sympathetic drive and the effects of RDN on arterial stiffness and 
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The ASAF trial is a prospective, randomised, controlled, multicenter, international clinical 
trial. Patients are not blinded for their procedure. 
Patient population, inclusion and exclusion criteria
The target group of patients are subjects aged <75 years, with paroxysmal or persistent AF, 
who have out of range hypertension (systolic >140 or >130/80 mmHg in diabetics and patients 
with chronic renal disease) and signs of sympathetic overdrive. Sympathetic overdrive 
is defined when patients show one or more of the following features: obesity (BMI >30), 
excessive blood pressure rise (peak systolic blood pressure >250 mmHg) on exercise stress 
testing, white coat hypertension (normal ambulatory blood pressure measurements despite 
hypertension in a clinical setting which is associated with an increase in sympathetic drive20), 
raised serum cortisol during illness or admission, hospital admission or fever induced AF, 
tachycardia induced AF during Holter monitoring or telemetry and/or diabetes mellitus. 
Patients should use at least 2 antihypertensive drugs or should be intolerant for medication. 
The following medication is seen as antihypertensive medication: angiotensin II blocker, ACE 
inhibitor, alpha blocker, beta blocker, calcium antagonist, diuretics, central acting agents and 
renin inhibitors. Apparent secondary causes for hypertension and/or AF should be excluded 
by a vigorous protocol. We hypothesize that the proportion of AF free survival after a single 
procedure of PVI will be 60% after one year compared to 80% in the PVI + RDN group. We will 
perform a log-rank test to test a hazard ratio of 0.437 (RDN + PVI versus PVI). 69 patients per 
group are required for a log-rank test to test a hazard ratio of 0.437, with a power of 0.80, a 
2-sided alpha of 0.5 and an expected drop-out of 10% per group assuming a 12 month accrual 
period and 12 months follow-up. For the sample size calculation the approach of Schoenfeld 
and Richter was used.
In order to be eligible to participate in this study, a subject must meet all of the following 
criteria: 1. The patient is willing and able to comply with the protocol and has provided written 
informed consent. 2. The patient falls within the target group as stated earlier. 3. Patient is an 
acceptable candidate for renal denervation treatment. 4. Patient is < 75 year of age. A potential 
subject who meets any of the following criteria will be excluded from participation in this 
study: 1. Documented left atrial diameter on trans thoracic echocardiography (PLAX > 4.5 
cm). 2. Contraindication to chronic anticoagulation therapy or heparin. 3. Previous left heart 
ablation procedure for AF. 4. Acute coronary syndrome, cardiac surgery, PCI or stroke within 
3 months prior to enrolment. 5. Untreated hypothyroidism or hyperthyroidism. 6. More 
than grade 1/3 valvular regurgitation and/or significant valve stenosis (modest or severe). 7. 
LVEF <45% and/or grade 3/4 diastolic dysfunction. 8. Enrolment in another investigational 
drug or device study. 9. Woman currently pregnant or breastfeeding or not using reliable 
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contraceptive measures during fertile age. 10. Mental or physical inability to participate in the 
study. 11. Planned cardiovascular intervention. 12. Life expectancy ≤ 12 months. 13. Renal artery 
stenosis >50% of the arterial lumen, or renal artery lumen ≤3 mm. 14. Dual or triple ipsilateral 
renal artery ostia not suitable for RDN. 15. Obvious secondary cause of hypertension. 
Patients who satisfy the entry criteria will be randomised by an automated system in order 
to minimize bias based on patient selection and baseline characteristics. The randomization 
will be generated with random permuted blocks with a 1:1 allocation of treatments. 
The control group will be the group that underwent pulmonary vein isolation. See figure 2 for 
the randomization into the two arms of this study.
Patients with paroxysmal or persistent atrial fibrillation
with out of range hypertension
(systollic > 140 mmHg or > 130/80 mmHg in diabetics and
patients with chronic renel disease)
or sings of sympathetic overdrive.
Patients should use at least 2 anti-hypertensives




PVI + RDN (N=69)
Figure 2. Each arm of the study contains 69 patients. The investigational groups will receive PVI + RDN. The control 
group will receive PVI only. 
Interventional group (1)
These patients will undergo renal artery denervation and pulmonary vein isolation. Renal 
artery denervation will be performed by femoral arterial catheterization, and cannulation 
of the renal arteries. A number of ablations will be performed in the left and right renal 
artery according to our previously described protocol. In a subset of patients, renal nerve 
stimulation (RNS) will be used to assess the completeness of ablation. Pulmonary vein 
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isolation will be performed by femoral vein cannulation, transseptal puncture, and circular 
antral radiofrequency or cryo-ablation of the pulmonary veins, with confirmation of isolation.
Control group (2)
These patients will undergo pulmonary vein isolation. Pulmonary vein isolation will be 
performed as stated above. No other sham procedure will be performed in the control group. 
Pre procedural measurements
Pre-treatment: 24 hour Holter monitoring or cardiac rhythm monitoring with a loop recorder 
(AF burden), lab tests, number of antihypertensives, 24-h ambulatory blood pressure 
monitoring, office blood pressure measurement. An internist with a special interest in 
hypertension treatment assesses the patients prior to randomization.
Procedure
Shortly the procedure is as follows. A complete workup including CT or MRI scan of the renal 
arteries is performed before the intervention and eligible candidates with symptomatic AF 
are included. The right femoral artery is punctured, and via a Seldinger technique a guiding 
wire is introduced. Afterwards a sheath is introduced. A pigtail catheter is introduced through 
the sheath and a contrast angiogram of the abdominal aorta is made depicting the renal 
arteries. Subsequently, the renal artery is cannulated with the multi-electrode Symplicity 
Spyral catheter through a guiding sheath. This catheter has the advantage of activating up 
to 4 electrodes to simultaneously deliver radio frequency energy, reducing the ablation time 
to 2 minutes. The ablation catheter is introduced up to the first bifurcation and extensive 
ablations according to our previously described protocol in both renal arteries, with 0.5 cm 
distance between ablation points. In a subset of patients the renal nerve stimulation (RNS) 
technique is used to assess completeness of renal denervation, providing us with more data 
and stimulation properties in a non-resistant hypertensive population21-23. 
Periprocedural measurements
Blood pressure measurement before and after intervention. Periprocedural blood pressure 
before intervention and after intervention. 
Follow up
Post treatment and follow up (3, 6 and 12 months): 24 hour Holter monitoring or cardiac 
rhythm monitoring with a loop recorder, lab and urine tests, number of antihypertensive 
drugs, 24 hour ambulatory blood pressure measurement, office blood pressure measurements. 
Specific drug adherence testing was not included in the ASAF study protocol. Although very 
important, this drug adherence issue is beyond the scope of our current study. A drug up-
titration scheme is not part of the ASAF study, most patients with atrial fibrillation who suffer 
from hypertension referred for treatment do not have uncontrolled or resistant hypertension.
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Main study end point
Time to first detection of AF >30 seconds, with the monitoring period starting 3 months after 
the intervention.
Secondary end points
1. AF burden after 12 months of follow-up, expressed in % of the monitoring period, in patients 
with continuous rhythm monitoring. The monitoring period starts 3 months after the 
intervention. 2. Blood pressure at 3, 6, 12 months after the intervention, and change in blood 
pressure compared to measurement before the intervention. 
Other endpoints
The other end points include laboratory measurements, ambulatory blood pressure 
monitoring, Holter monitoring, rhythm assessments (AF burden) from implantable 
continuous loop recorder and exercise stress tests.
Use of co-intervention
In all groups, Vaughan-Williams class 1c, class II, class III (only sotalol) and/or class IV 
antiarrhythmics can be used. The goal is to stop class 1c or class III antiarrhythmic medication 
after 3 months after the intervention. The physician can re-initiate these antiarrhythmics 
when needed, with proper documentation of these changes in medication. If used, 
amiodarone should be stopped at least 3 months before the intervention. Antihypertensive 
medication should not be changed, unless grade 3 hypertension (office BP >180/110 mmHg) 
persists, or symptomatic orthostatic hypotension is present. Physicians are expected to use 
only antihypertensive drugs of the following classes: angiotensin II blocker, ACE inhibitor, 
beta blocker, calcium antagonist and diuretics.
Early termination of the study
The study will be terminated if safety data indicate that treatment is associated with important 
AEs or in case of unacceptable patient risk exposure. In that case an unscheduled interim 




The ITT population consists of patients who have met the study entry criteria and have 
granted informed consent to participate in this study. These criteria are a prerequisite 
to randomization. This analysis population is also referred to as the all Randomised 
Subjects Set (RSS), or Enrolled Set. All analyses will be based on this population if there is 
post-randomization data for every patient. All baseline characteristics (e.g. summary of 
demographics) will be summarized on this analysis set. All results listings will be based on 
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the ITT population.
Full Analysis Set (FAS)
The FAS consists of patients from the ITT population who have treatment-related data post 
randomization. This analysis set is as complete as possible and as close as possible to the ITT 
population. If the FAS population is not, in practice identical to the ITT population, the FAS 
will be used for all non-baseline analyses. 
Per Protocol Set (PPS)
The PPS population consists of all subjects from the FAS set with evaluable data and who have 
demonstrated full compliance with the study protocol (i.e. there is absence of any major 
protocol violations including the violation of entry criteria). Minor protocol deviations 
would be judged at the Data Review Meeting and deemed as such, before subjects can be 
retained in this population. The problems that lead to the exclusion of subjects to create the 
PPS, and other protocol violations, will be fully identified and summarized per treatment 
group, indicating frequencies, date and time of occurrence, where applicable.
Description of Statistical Analysis
We will perform an intention-to-treat analysis, if data permits. Otherwise the next most 
exhaustive study population (FAS) will be used. The eventual study population used will be 
explicitly stated for all results tables and figures generated. All line listings will be based on 
the ITT population and the study population would not need to be specified in the listings.
Descriptive statistics will be provided for all variables considered in the analysis. Continuous 
variables will be summarized descriptively providing, where applicable, the number of 
patients (N), mean, standard deviation (SD), median, minimum (min) and maximum (max), 
and interquartile range. Categorical variables will be expressed as counts and percentages 
(%). Percentages will be calculated according to the number of patients for whom data are 
available. P-values and accompanying Effect Size (Eta-squared values) statistics will be 
presented where applicable. The former will be used as a flag to filter for subsets of statistically 
significant results during comparison of treatment groups, if required. Unless otherwise 
stated, calculations will be performed per treatment group. 
Primary endpoints
For key results changes (and percentage change, if deemed appropriate) from baseline will be 
summarized descriptively providing, the N, Nmiss (number missing), mean, SD, median, min 
and max; where applicable. The primary study endpoint is time to first detection of AF >30 
seconds, with the monitoring period starting 3 months after the intervention. The primary 
objectives are to investigate (I) if RDN in combination with PVI prevents AF; (II) if there is 
superiority of the RDN procedure in combination with the PVI procedure in contrast to the 
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PVI procedure alone. The primary outcome measure will be tested by Kaplan Meier curves and 
log-rank tests. The Kaplan Meier curves will indicate freedom of AF >30 seconds after 1 year of 
follow-up with the monitoring period starting 3 months after the intervention. 
For the first part of the primary objective, we will test the absolute outcome values (incidence 
of success vs incidence of non-success for the PVI+RDN group) statistically by using Pearson’s 
chi-squared test. In case of rare events (the expected number per cell lower than 5 in more 
than 20% of the cells) the Fisher Exact test will be used. Two-sided 95% confidence intervals 
of the difference in percentages between the incidence groups will be calculated using 
exact methods. For the second part of the primary objective, we will test for significance 
of differences between PVI+RDN versus PVI. We will compare the survival distributions of 
PVI+RDN versus PVI using a log-rank test. 
Differences in secondary endpoint absolute outcome values (incidences) will be statistically 
tested between groups by using Fisher’s exact test or Pearson’s chi-squared test. Differences 
in means of continuous data will be statistically tested by performing Student’s t-test or, 
in case the data are not normally distributed, the Mann-Whitney-Wilcoxon test. Changes 
in continuous secondary endpoints compared to measurements before the intervention 
(blood pressure and heart rate response, heart rate variability, biomarkers, arterial stiffness 
measures) will be tested by paired t-tests. If the normality assumption is not met we will 
perform Wilcoxon Signed Rank Tests.
For blood pressure (systolic and diastolic) effects over time a two way repeated measures 
ANOVA will be performed. If the normality assumption is not met we will transform the data. 
We will test the interaction between treatment (PVI+RDN versus PVI) and time.
ANOVA assumes sphericity (compound symmetry), i.e. all the correlations of the outcome 
variable between repeated measurements are equal and all the variances of the outcome 
variable at each of the repeated measurements are equal. If the sphericity assumption is 
violated we will perform ANOVA with a Greenhouse and Geisser correction.
DISCUSSION
This study is a multicenter randomised controlled trial in which RDN on top of PVI is one 
of the arms as a therapeutic procedure for AF. This study will elucidate the added benefit of 
renal denervation to standard AF ablation in the prevention of AF recurrence in hypertensive 
patients with signs of sympathetic overdrive. 
In animal studies, renal denervation resulted in less inducibility of AF with aggressive 
programmed electrical stimulation. Furthermore, it resulted in less persistent AF when AF 
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was still inducible in dogs. Besides, in post myocardial infarction rats, renal denervation 
resulted in a higher left ventricular ejection fraction, significantly improved hemodynamic 
indicators, and lower NT-pro-BNP, as compared with controls.24-26
In a small sample of patients with paroxysmal and/or persistent AF and resistant hypertension, 
renal denervation in addition to pulmonary vein isolation, resulted in significantly less 
patients with AF episodes, compared to patients undergoing pulmonary vein isolation 
only.17 This study however, had very important limitations, i.e. the small number of patients 
included, the changes that have been made to the design of the study and the change in end 
points. Most of these issues have been addressed by Staessen et al.27 Apart from one change in 
the study design, dropping the RDN only arm, none of the mentioned limitations are present 
in the ASAF study. In several studies, including randomised controlled trials, it was shown that 
renal denervation resulted in a significant and durable reduction of blood pressure and less 
need for antihypertensive medication use and a higher proportion of patients reaching blood 
pressure goals. Renal denervation resulted in a reduced renal resistive index and incidence of 
albuminuria without adversely affecting glomerular filtration rate or renal artery structure. 
In all studies, renal denervation appeared to be a safe, with a <1% complication rate (renal 
artery dissection, groin bleeding, etc.), without any development of renal artery stenosis.28-30 
Importantly, there was zero mortality associated with the intervention. 
The Symplicity HTN-3 trial however, a sham controlled randomised blinded study, failed to 
meet both its primary (office systolic blood pressure reduction) and its secondary (mean 
24-h ambulatory blood pressure) endpoints.31 One of the most important concerns raised 
after this trial, was the lack of an acute endpoint. Our group assessed the feasibility of renal 
nerve stimulation (RNS) before and after the procedure to assess this endpoint.21 Recently we 
demonstrated that RNS can be used to predict the outcome to RDN in a small cohort.22 RNS 
also elicited an increase in BP in accessory renal arteries after denervation of the main arteries, 
underlining a proof of concept.23 Question remains whether a RDN without a procedural 
endpoint will be effective, but that is beyond the scope of this trial.
We have chosen different inclusion criteria than the classic one for resistant hypertensive 
patients, since our primary goal is to prevent AF, rather than treating resistant hypertension. 
If higher sympathetic tone is present through the renal nervous system, a rise in peripheral 
resistance and thus hypertension should be present. We therefore include patients who use 
two or more antihypertensives and have out of range hypertension. 
Additionally, we chose to target patient groups in which previously a higher sympathetic 
tone was proven, such as diabetics, hypertensive patients with significant white coat effect, 
patients with tachycardia or illness mediated AF and patients with excessive blood pressure 
rise on exercise testing. 
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Our primary endpoint will be recurrence of AF/AFL/AT post-ablation, after a blanking 
period of 3 months after the interventional procedure, which is a frequently used and 
well known endpoint. Recurrence of AF/AFL/AT after ablation will be defined according to 
EHRA guidelines. In patients with continuous loop monitors, we will assess AF burden as a 
secondary endpoint. Treating AF by RDN can be mediated through different mechanisms. 
First, one of the most important risk factors for incident AF, but also for recurrent AF after 
treatment by ablation, is hypertension. We expect that after an added RDN procedure, both 
resting and stress blood pressure will be lower. Furthermore, RDN resulted in improved 
diastolic function and thus less atrial pressure and stretch, which is associated with less 
inducible AF in different studies.32 Finally, a reduction of sympathetic tone by RDN resulted 
in less atrial and ventricular ectopic beats, and even less ventricular tachycardia. By the 
reduction of ectopic beats, fewer trigger moments for the initiation of AF could be present, 
aiding in the prevention of recurrent AF.30 A single blind study is currently investigating the 
effect of RDN on AF burden compared to anti arrhythmic drug regiments.33 This study will 
contribute to assessing the effect of RDN on AF, but does not cover the additional effect of 
RDN on PVI. Another interesting trial currently recruiting patients is the Symplicity AF.34 The 
main goal of the Simplicity AF trial is to test the feasibility and safety of performing both renal 
denervation and pulmonary vein isolation. ASAF is an investigator initiated trial. The primary 
endpoint of ASAF trial is AF free survival after a combination of pulmonary vein isolation 
and renal denervation compared to pulmonary vein isolation only. The most important 
difference between the Symplicity AF trial and the ASAF is the emphasis on hypertension in 
the Symplicity AF trial. Hypertension is a modifiable risk factor contributing in many patients 
who suffer from atrial fibrillation. By including patients with office systolic BP >150 mmHg 
whilst on a drug regimen with 3 antihypertensives, this study automatically targets a truly 
hypertensive population. ASAF trial focuses on the enhanced sympathetic drive in patients 
with atrial fibrillation. Independent of hypertension, other conditions are accompanied by 
sympathetic overdrive. We test the hypothesis that sympathetic overdrive can be targeted by 
RDN. In addition to blood pressure lowering effect, RDN may have anti-arrhythmic effects. 
Since the publication of the Simplicity HTN 3 trial, several other important trials have been 
published. These studies partly restore the efficacy of RDN in lowering BP. For example the 
DENERHTN trial by Azizi et al.35 demonstrate the additive effect of RDN on top of stepped 
care standardized antihypertensive treatment. Another more fundamental randomised trial 
(SPYRAL HTN OFF-MED) took resistant hypertensive patients off their drug regimen and 
divided them between RDN and sham procedures. RDN significantly lowered BP in the RDN 
arm.36 In the light of these recent landmark studies we are confident that RDN is still a viable 
option to interfere with possibly multiple factors influencing and maintaining AF.
Concluding, our present trial is the first multicenter randomised, controlled trial, assessing 
the effect of RDN as adjunct therapy on top of standard AF ablation therapy, in the prevention 
of recurrent AF. 
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Patients affected with hypertension can be graded into different categories of severity ranging 
from ‘high normal’ to grade III hypertension. A subset of patients remains hypertensive 
despite being treated with a drug regimen containing at least three different classes of drugs 
or when there is documented intolerance for these classes. These patients suffer from resistant 
hypertension. Resistant hypertension is diagnosed in approximately 15% of the hypertensive 
population. These patients are at high risk of developing cardiovascular complications 
and require extensive medical attention, since it is hard to diagnose resistant hypertension 
without careful monitoring the effects of the intended treatment. Patients are often well 
aware of their risk and are very motivated to undergo invasive treatment for their medication 
resistant hypertension. 
The hypertension community has awaited other solutions than lifestyle interventions and 
medical therapy to treat resistant hypertension. With the emergence of renal denervation, a 
solution seemed to have been found. The initial reports based on unblinded studies on blood 
pressure lowering effects of renal denervation were very promising. Renal denervation (RDN) 
could be a new treatment modality in patients with resistant hypertension. The SYMPLICITY-
HTN-2 trial suggested a major reduction with RDN in systolic BP based on office-based 
measurement of BP. However, ambulatory BP is a state-of-the art technique for measuring 
BP in patients with treatment-resistant hypertension. Poor drug adherence is common in 
treatment-resistant hypertension, but this was not monitored in SYMPLICITY-HTN-2 which 
made the study vulnerable to the Hawthorne effect (i.e. a change in behaviour when people 
know they are being observed). The magnitude of response varied between nonresponse to 
the so called super-response to renal denervation in a subgroup of patients. 
However, data from 3 blinded randomised trials failed to demonstrate a benefit of RDN, and 
therefore an ongoing large international trial was stopped prematurely. SYMPLICITY-HTN-3 
(5) included sham and ambulatory BP measurement that balanced the Hawthorne and other 
patient and investigator unspecific effects but BP lowering caused by RDN was not significant 
in this trial. It was then suggested that SYMPLICITY-HTN-3 was not rigorously executed and 
that RDN was suboptimal due to various technical issues related to the renal artery anatomy 
and technique for delivery of energy. But analyses were post-hoc, and SYMPLICITY-HTN-3 
findings were in line with results of other trials, and the meta-analyses of the first wave of 
properly done randomized studies of RDN did not show BP lowering effects of RDN whether 
SYMPLICITY-HTN-3 was included or not, or whether sham was a part of the design or not. This 
had led to uncertainty of the place of RDN in the treatment of resistant hypertension. In 
the most recent ESC/ESH Arterial Hypertension (Management of ) guidelines, device-based 
therapies, such as RDN, are not recommended (class III, level of evidence B) for the routine 
treatment of (resistant) hypertension, unless in the context of clinical studies and RCTs, until 
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further evidence regarding their safety and efficacy becomes available. As one of the many 
RDN investigators stated: “We have seen the rise and fall of renal artery denervation, and we 
hope that we shall witness the resurrection.” (Bhatt, Deepak L. MD, in Ruminations about 
Renal Denervation).
This thesis describes the development of renal nerve stimulation (RNS) in the setting of RDN. 
After publication of the disappointing results of the HTN-3 trial, many explanations were 
given to clarify the results of this study. Some people believed it was due to the learning curve 
of newer centres, inspired by the initial results. More experienced centres seemed to have a 
more pronounced drop in blood pressure. Another explanation is inefficient ablation by not 
applying enough radiofrequency energy to the wall of the renal arteries. This is in analogy 
with ablation for AF in which measuring and adjusting to contact force might contribute to 
the effectiveness. 
However, we chose a different path. From the perspective of a cardiac electrophysiologist, 
performing a renal denervation without a procedural endpoint does not make sense. 
Repeating the analogy of pulmonary vein isolation for AF ablation, isolation of the veins is 
checked with a circular mapping catheter after ablation to make sure the ablation has been 
performed successfully. In Isala Heart Centre the renal denervation procedures are carried 
out by cardiac interventional electrophysiologists, in contrast to majority of centres where 
these procedures were performed by interventional cardiologists or radiologists. 
Looking for a procedural endpoint for renal denervation we came up with the development 
of renal nerve stimulation. The technique enables the operator to perform renal denervation 
using a more functional approach. 
This thesis describes our clinical studies regarding potential mechanisms underlying the 
variable response to renal denervation and the results of a novel approach using renal nerve 
stimulation to guide renal denervation. Both of them are aspects that have to be addressed 
to determine the role of renal denervation in the treatment of resistant hypertension. RNS is 
an important improvement of the RDN technique and provides operators with a procedural 
endpoint. This sets our studies apart from the large negative studies studying the effect of 
RDN. Our studies provide more insight into the effect of RDN, after the large negative studies 
on this topic. In addition, we try to elucidate the potential mechanisms why RDN might work 
in hypertension, which may also shed light on the results of earlier studies in this field.
THE DEVELOPMENT OF RNS
This thesis describes the development of RNS as a tool to localize renal perivascular nerves. 
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The first step in the development of RNS was the feasibility study in patients with resistant 
hypertension. Chapter 2 elaborates on the process of different setting for pacing output, 
pacing frequency and duration of the electrical stimulation. Studying the effects of different 
settings was a very interesting experience since human data on RNS is scarce and most of the 
ideas have only been tested in animal models, such as a canine model. We carefully monitored 
the effect of RNS on the cardiovascular system and concluded that RNS in the setting of a RDN 
procedure was safe in our patient population. The most important ‘serious adverse event’ was 
a temporary decline in renal function in one patient, which normalised after discontinuation 
of nephrotoxic medication. 
One may argue that renal nerve stimulation is painful and that it will cause a pronounced 
vagal reaction to pain induced by pacing. However, our acute blood pressure findings were 
related to the post RDN outcome based on 24 hour ambulatory blood pressure monitoring. 
These findings have been explored in chapter 3. Because of the significant relationship 
between the RNS data and the blood pressure lowering effect, it is unlikely that RNS induced 
blood pressure decrease is related to pain.
Chapter 4 builds a bridge between RNS and predictors of response to RDN. We demonstrated 
an important aspect of RDN in patients with accessory renal arteries. Since these accessory 
arteries are common and their role not fully delineated, we investigated them with RNS. 
After a ‘successful’ denervation of the main renal arteries, an increase in BP can still be invoked 
by RNS in the accessory arteries. A successful denervation was defined as an increase in BP due 
to RNS before RDN and a blunted increase in BP after RDN of the main arteries. Even after 
denervation of the main arteries, a BP increase could be invoked with RNS in the accessory 
arteries. These findings demonstrate an important relationship between renal vasculature 
and responder rate. 
Chapter 5 describes the acute effects of RNS on the blood pressure response in patients. 
Including patients in the RNS study yielded interesting information with regards to blood 
pressure response patterns. In accordance with our hypothesis, blood pressure increased 
at most sites (almost two-third of the sites), due to activation of sympathetic nerve tissue. 
There was no blood pressure change after RNS at other sites. This procedure enables the 
operator to map sympathetic nerve bundles along the perivascular space of the renal arteries. 
In response to stimulation at sites without sympathetic nerves, no alteration in blood 
pressure was observed. High frequency electrical stimulation is a functional approach and 
exact relationship between anatomic localisation of nerves and RNS response remains to be 
elucidated.
Interestingly, we identified sites at which the blood pressure dropped in response to RNS. 
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We speculate that blood pressure decrease was elicited by stimulation of vagal nerves since, 
anatomically, the parasympathetic ganglia are located in close proximity to these RNS sites. 
Ablation of these ganglia would serve no purpose in the treatment of hypertension. 
RENAL DENERVATION AND HYPERTENSION
Since the clinical evidence of RDN as an effective BP-lowering technique is conflicting, and 
based on large RCTs currently not recommended for the routine treatment of (resistant) 
hypertension, the place of RND in the treatment of drug resistant hypertension is uncertain. 
The multifactorial underlying pathophysiology in these patients makes it hard to establish 
one factor that will solve hypertension in the entire 15% of drug resistant patients.
In our database, approximately one third of the patients responded well to RDN (substantially 
lower blood pressure, reduction in number of antihypertensive drugs). One third responded 
moderately (slightly lower blood pressure or reduced dosages of the same drug regimen). 
One third of the patients responded poorly with no change in blood pressure, or even an 
increase in blood pressure in some patients. There are several factors that need to be taken 
into account before we can interpret these data. None of these patients had a strict check 
of drug compliance. Some centres admitted their patients to the general ward and checked 
the BP lowering effect of clinically provided medication intake before diagnosing drug 
resistant hypertension. Other hypertension centres put their patients on a trial period with 
spironolactone to exclude hyperaldosteronism. Our patients were screened vigorously to rule 
out secondary causes of hypertension before diagnosing drug resistant hypertension. Hereby, 
we aimed to exclude hormonal disturbances such as hyperaldosteronism. Patients eligible 
for RDN after careful screening were very motivated to undergo the invasive procedure. We 
assumed these patients were compliant to the prescribed drugs. Of note, a drug compliance 
of 100% is not realistic in any population, so this issue remains arguable. Those patients 
who responded well to the renal sympathetic denervation therapy might have a lower risk 
of developing cardiovascular endpoints, optimal management of blood pressure with a 
reduced number of antihypertensive drugs and as a consequence may experience less side 
effects. We believe that in the future there may possibly be a place for renal denervation in 
the treatment of drug resistant hypertension, if (preferably sham-) controlled studies are 
positive. The prospective, open-label randomised controlled trial with blinded endpoint 
evaluation DENERHTN study and the single-blind, randomised, sham-controlled, proof-of-
concept SPYRAL HTN OFF MED study demonstrated a positive result for RDN. And we have 
to take into account that RDN only requires a one-time procedure instead of drug adherence 
with possible side effects. RDN is possibly the treatment of choice for younger patients, that 
would otherwise have to use a certain drug regimen for lifetime. Our reflections on the role of 
RNS in the setting of RDN have been summarised in the review (chapter 6). 
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RENAL DENERVATION (RDN) IN ATRIAL FIBRILLATION
This thesis includes one of the future aspects of renal denervation. AF is subject to a different 
discussion regarding the role of the autonomic nervous system in triggering and maintaining 
AF. Medical therapy falls short in treating AF since long-term sinus rhythm is achieved in 
only 30-40% of patients. Catheter ablation is the next step to establish and maintain sinus 
rhythm and has a success rate ranging from 60-70% of AF-free survival after a single procedure. 
This leaves a significant number of patients who remain symptomatic post-ablation and 
could probably benefit from additional treatment. One of adjunct therapy options is renal 
sympathetic denervation. The concept behind renal denervation for AF is to suppress triggers 
caused by fluctuations in the sympatho-vagal balance. Majority of patients who wake up with 
a paroxysm of AF do not have overt structural heart disease and a vagal component is quite 
likely in these patients. In patients with enhanced sympathetic tone and AF, risk factors such 
as hypertension, obesity, diabetes mellitus can be identified. Furthermore, some patients 
develop sympathetic AF during episodes of fever for example. Enhanced sympathetic tone may 
induce AF. A similar effect is seen when patients develop AF during exercise. For this reason, 
the potential role of RDN on top of pulmonary vein isolation is discussed in chapter 7. Renal 
denervation is a possible adjunct treatment in patients with AF and enhanced sympathetic 
tone undergoing catheter ablation. We hypothesised that if patients are identified with 
sympathetic AF, they could possibly benefit from renal denervation. The ASAF study is an 
ongoing international multicentre randomised controlled trial which tests the role of renal 
denervation in achieving and maintaining sinus rhythm on top of pulmonary vein isolation 
compared to pulmonary vein isolation alone. 
If renal denervation combined with pulmonary vein isolation proves to be superior to 
pulmonary vein isolation alone, a potential anti-arrhythmic role for renal denervation will 
be established. As of May 2019 only one meta-analysis by Atti and colleagues in the Journal 
of Cardiovascular Electrophysiology has analysed 6 studies, 4 of which were randomised 
studies. The total number of patients was 432 patients. RDN on top of PVI did contribute to 
a significantly lower recurrence of AF in patients with a history of hypertension (pooled RR 
0.58 [0.47-0.72], P <0.001).
The ASAF trial is important because of the currently recruited number of patients and the 
scarcity of studies investigating the role of RDN in AF that are actively including patients. As 
of October 2018 only a few studies are recruiting patients. The Simplicity AF trial is currently 
recruiting patients with paroxysmal and persistent AF in the United States. The Chinese 
SWAN-cpAF study has been recruiting patients since 2012 without reaching the intended 100 
patients. A South-African study (RDPAF1) is investigating the preventive effect of RDN on the 
development of AF in hypertensive heart disease. 
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RENAL DENERVATION IN THE LIGHT OF NEW RESEARCH
This thesis referred to the following statement: “we have seen the rise and fall of renal 
denervation and we hope to see its resurrection”. This is a statement from 2016 when the 
HTN-3 trial devastated the initial hope that RDN would solve resistant hypertension, and led, 
among others, to the class III recommendation (i.e. “not recommended”) in the latest ESC/
ESH guidelines for the routine treatment of (resistant) hypertension. However, the SPYRAL 
OFF and ON MED studies have shined new light on the efficacy of RDN. The results of the 
SPYRAL OFF MED demonstrated a significant effect of RDN when compared to sham control. 
The SPYRAL ON MED had similar, but even more pronounced results. It is reassuring that the 
procedure can bring about a blood pressure lowering effect. However, we have come a long 
way from the initial procedure and the current procedure.
When RDN was first performed, 4-8 ablation points per renal artery were placed, in hopes of 
permanently destroying the surrounding sympathetic nerve tissue. The SPYRAL ON MED has 
a staggering average of 45.9 ablation points. 
The evolution from carefully selected point to ‘as many as you can fit in’ has definitely changed 
the extent of damage done to the sympathetic nerves. The procedure has become more 
effective with more pronounced blood pressure drops in larger proportions of the included 
patients. However, the more damage you do, the more worried you should be about long term 
effects like kidney function and renal artery stenosis. With progressive insight in the number 
of ablation points, the currently available follow-up is insufficient to determine these effects. 
The role of RDN in accessory arteries has been studied as well. With the advancement 
of technique and catheters, smaller and smaller arteries could be denervated without 
compromising the artery. Initially, patients with a more complex vasculature were not 
included in the RDN studies, or these patients demonstrated a less impressive blood pressure 
lowering effect. Currently accessory arteries are being treated in the same setting as the main 
branches, whenever that seems feasible. 
Other groups have diverted their focus to contact force, to ensure proper contact between 
the catheter and the renal arteries for subsequent ablation. An even more different approach 
has been chosen in the RADIANCE-HTN-SOLO, to replace radiofrequency with ultrasound 
energy to destroy the sympathetic nerves. The initial results favour RDN over sham 
procedures. Investigators relied on patient-reported antihypertensive drug use. Reported 
medication use was more common in the sham group, but hidden use was not evaluated by 
drug measurements in blood. Assuming that hidden drug use was not more common in the 
treatment group, RADIANCE-HTN-SOLO together with the SPYRAL-OFF and ON-MED trials 
may provide the first true trial evidence that RDN lowers BP. Another important study is the 
ULTRASOUND-HTN, comparing three techniques to denervate the renal arteries. Patients 
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with daytime ambulatory BP more than 135/85 mmHg and less than 170/105 mmHg after a four-
week discontinuation of 1-2 antihypertensive drugs were randomised to RDN (n=74) or sham 
(n=72). The primary endpoint was change in daytime ambulatory systolic BP at 2 months in the 
intention-to-treat population. Endovascular ultrasound RDN reduced daytime ambulatory 
systolic BP with 6·3 mm Hg more than sham (p=0·0001). Perhaps a switch in energy source is an 
important step in perfecting RDN procedures, especially after the REDUCE HTN: REINFORCE 
study failed to meet its primary efficacy endpoint. The latter study investigated ablation with 
radiofrequency energy, but was terminated because a preliminary analysis demonstrated no 
difference between the interventional and the sham procedure groups. 
However, there is one major difference between the empiric RDN results and the development 
of RNS. No matter how many ablation points have been placed, no matter which arteries 
were targeted for denervation (main, accessory or both) and no matter what technology is 
used to denervate the arteries with, none of these improvements identify and localise the 
perivascular nerve bundles. A successful RDN procedure hinges on successfully destroying 
the targeted nerve fibres. RNS combines localising the sympathetic nerves with preventing 
inadvertent ablation of other tissue. Therefore RNS should be explored in a wider variety of 
patients. 
CONCLUSION
The aim of our studies was to increase our insights into the mechanisms of RDN, improve 
patient selection and technique to increase response rate to RDN. We were the first assessing 
the feasibility of RNS in humans with resistant hypertension, undergoing RDN. We showed a 
significant temporary rise in BP due to RNS, and a large reduction of RNS-induced BP rise after 
RDN. Furthermore, we reported that the magnitude of reduction of RNS-induced BP changes 
after RDN were strongly associated with reductions of BP measured with 24-h ABPM during 
follow-up after RDN. The underlying pathophysiological mechanisms of RNS and the effects 
on arterial blood pressure dynamics remain to be fully elucidated. Future studies exploring 
the role of RNS guided RDN in larger cohorts are warranted. 
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Hoge bloeddruk is een van de meest voorkomende risicofactoren voor het ontwikkelen 
van hart- en vaatziekten. Hoge bloeddruk is goed behandelbaar met medicatie. Er is 
echter een groep patiënten welke niet de streefwaarde van de bloeddruk bereikt met drie 
middelen waaronder een plastablet. Deze groep patiënten dient gescreend te worden voor 
een onderliggende oorzaak van de hoge bloeddruk (bijv. hormonaal bepaald, op basis 
van nierslagadervernauwing, slaap-apneu syndroom etc.). Als deze oorzaken niet worden 
gevonden resteert er een groep patiënten met medicatie-resistente hoge bloeddruk. Deze 
groep mensen heeft allicht baat bij een ingreep aan de zenuwen die de nierslagaders 
omgeven. Deze ingreep wordt renale denervatie (RDN, renal sympathetic denervation) 
genoemd. Het idee dat de nieren een te hoge bloeddruk maken op basis van een verhoogde 
zenuwactiviteit is niet nieuw. Vroeger werd deze ingreep operatief verricht, maar met de 
opkomst van de medicatie tegen een hoge bloeddruk (antihypertensiva) raakte de RDN 
procedure uit zwang. Met de opkomst van catheters en daarmee de mogelijkheid om via de 
liesslagader bij de nierslagaders te komen, kreeg renale denervatie een nieuw leven. Vanuit de 
binnenzijde van het bloedvat kan de ingreep verricht worden. Dit biedt hoop aan patiënten 
die gebonden zijn aan een uitgebreid schema met antihypertensiva. De eerste resultaten 
van de studies die werden verricht om de effectiviteit van RDN te onderzoeken waren erg 
goed. Dit gaf de behandeling een enorme boost. Echter een grote studie waarin patiënten 
werden verdeeld tussen een echte RDN procedure en een ‘nep-procedure’, resulteerde in een 
teleurstelling. De bloeddrukdaling was vergelijkbaar in beide groepen. Er is binnen de wereld 
van onderzoekers naar RDN veel gediscussieerd over wat de oorzaak zou kunnen zijn en 
verscheidende facetten van deze discussie zijn onderzocht. Er is o.a. gekeken naar patiënten-
selectie, een vast schema titreren van de medicatie, stoppen met de medicatie vooraf aan de 
behandeling en de deelnemende centra. Om de ingreep zelf te verbeteren is gekeken naar het 
aantal ablatie punten, ablatie voorbij de eerste splitsing van de nierslagader en zelfs naar de 
kracht waarmee de catheter contact maakt met de wand van de nierslagader. Wat nog ontbrak 
was een manier om de zenuwvezels welke doorgebrand moeten worden (de sympathische 
zenuwvezels, van het actieve zenuwstelsel) op te sporen tijdens de ingreep. Het onderzoek 
dat wordt beschreven in dit proefschrift gaat in op een uitbreiding van de RDN procedure 
met een stimulatietechniek die de zenuwvezels activeert. Tijdens de procedure wordt met 
elektrische energie de sympathische zenuwvezels geactiveerd, welke op hun beurt weer een 
stijging van de bloeddruk veroorzaken. De uitbreiding hebben wij renale zenuwstimulatie 
genoemd en afgekort tot RNS. In hoofdstuk 1 van dit proefschrift wordt uitgelegd hoe het 
proefschrift is opgezet. In hoofdstuk 2 wordt beschreven dat de nieuwe RNS-techniek mogelijk 
is bij mensen. In hoofdstuk 3 wordt aangetoond dat als de procedure een succes is volgens 
de RNS-techniek, de daling in de gemiddelde bloeddruk over 24 uur ook groter is dan bij de 
groep bij wie de RDN volgens RNS minder goed is gelukt. In hoofdstuk vier laten we zien dat 
als de RNS techniek een goede RDN procedure voorspelt in de hoofdslagaders naar de nieren, 
er nog steeds sympathicusweefsel kan bestaan in de zijtakken. Dit past goed bij de bestaande 
literatuur waarin bekend is dat patiënten met een ingewikkeldere bloedvat voorziening 
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naar de nieren minder snel een goede reactie op RDN laten zien. De ervaring die is opgedaan 
met RNS gaf meer inzicht in de verschillende manieren waarop gereageerd wordt op RNS. 
Er zijn drie patronen te onderscheiden. In de eerste plaats is er de stijging in de bloeddruk 
welke ook wordt verwacht en aldaar zal ablatie (het wegbranden van de zenuwvezels) dan 
ook nodig zijn. Naast de stijging is er ook géén bloeddrukreactie mogelijk. Dit komt overeen 
met een stuk nierslagader waar geen sympathicusweefsel omheen zit. Ablatie is hier dan ook 
niet zinvol. We ontdekten ook plaatsen waar er een tegenovergestelde reactie plaatsvond 
met een vertraging in het hartritme en een bloeddrukdaling. Dit kan berusten op activatie 
van het ‘parasympathische’ zenuwstelsel, welke de tegenhanger is van de sympathicus en 
gebruikt wordt in rust en bij het verteren van voedsel. Ablatie aldaar is onwenselijk en kan 
met RNS voorkomen worden. In hoofdstuk 6 bespreken we de techniek als eindpunt voor 
een goede RDN procedure waarin wordt betoogd dat de techniek routinematiger toegepast 
zou moeten worden. Tot slot wordt in hoofdstuk 7 besproken dat gezien de heropleving 
van RDN procedures ook naar toepasbaarheid bij andere ziektes gekeken moet worden. 
Atriumfibrilleren (boezemfladderen) is een ritmestoornis van de voorkamers van het hart. 
Dit geeft een verhoogde kans op een herseninfarct, maar is ook een voorspeller van slechte 
uitkomt bij allerlei andere ziektebeelden. Met medicijnen alleen wordt maar in beperkte 
mate het hartritme hersteld naar het normale hartritme (sinusritme). Om de ritmestoornis 
te behandelen kan er in het hart een ablatie uitgevoerd worden. Echter uit dierexperimenteel 
onderzoek een kleine onderzoeken bij mensen blijkt dat er mogelijk ook een grotere kans is 
op het behoud van sinusritme als RDN wordt toegevoegd aan de ablatie in het hart. Om dit uit 
te zoeken is de ASAF studie opgezet. De studie loopt momenteel nog. Concluderend beschrijft 
dit proefschrift de mogelijkheid om RNS toe te voegen aan de huidige RDN procedure om 
zo het resultaat van de behandeling te voorspellen en tijdens de procedure te beoordelen 
of de ingreep beëindigd kan worden. De waarde van RNS maar ook de keerzijde worden 
besproken in de verschillende hoofdstukken. Het proefschrift eindigt met een voorzet voor 
de verbetering van de behandeling van de ritmestoornis atriumfibrilleren. 
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